| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
OraSure Technologies, Inc.$4.29
+0.04 (+0.82%)
Market Cap
248.54 M
EPS
-1.04
P/E Ratio
-
Value Trade
3.27 M
SEC Financials
Q1 2026Dilution Risk
Revenue
27.93 M
R&D Expenses
13.65 M
Operating CF
-13.89 M
Total Assets
379.17 M
Total Liabilities
65.84 M
Equity
313.32 M
D/E Ratio
12,345
19.93 %
Week
13.52 %
1 Month
28.01 %
3 Month
71.09 %
6 Month
-63.24 %
5 Year
69.88 %
All Time
Cash Data
Cash Position
176.96 M
Monthly Burn
4.63 M
Runway
36.3 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
193.70 K
52 Week Range
2.08 - 3.82
% held by Insiders
6.63 %
% held by Institutions
85.26 %
Enterprise Value
112.04 M
Total Shares
71.72 M
Short %
4.5 %
Float Shares
68.35 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OSUR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OSUR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OSUROraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, enabling at-home self-collection for STI testing. This advancement allows for convenient sample collection while maintaining sample integrity. The kit supports Roche's molecular diagnostic systems and aims to improve access for underserved populations, facilitating scalable testing and public health initiatives.
Read more →OSUROraSure Announces First Quarter 2026 Financial Results
OraSure Technologies, Inc. reported a revenue of $27.9 million for Q1 2026, surpassing its guidance midpoint. The company highlighted gross margin expansion and a strong balance sheet, which positions it well for growth and potential acquisitions. OraSure aims to decentralize diagnostics to improve healthcare accessibility and affordability.
Read more →OSUROraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the "Company" or "OraSure") contains certain "forward-looking statements" within the me
OraSure Technologies, Inc. has provided an investor update discussing its transformation strategy and financial performance. In Q1, the company reported a 4% growth in total revenue, demonstrating positive traction in its core business segments. The update highlights key operational improvements, including a focus on disciplined execution and the return to breakeven for its core business. Additionally, there is an optimistic outlook for growth driven by innovation and improved visibility into funding for critical testing programs.
Read more →OSUROraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. will announce its first quarter 2026 financial results during an earnings call scheduled for May 6, 2026. The call will take place at 5 p.m. ET and will be accessible via a webcast on the company's investor relations page. This event is part of OraSure's commitment to transparency and stakeholder engagement.
Read more →OSUROraSure Technologies Appoints John D. Bertrand to its Board of Directors
OraSure Technologies has appointed John D. Bertrand as an independent director to its Board of Directors. His extensive experience in healthcare technology and AI-enabled diagnostics is expected to bolster the company's strategic initiatives. Additionally, OraSure plans to seek shareholder approval to declassify its Board at the upcoming 2026 Annual Meeting, reflecting its commitment to governance and shareholder engagement.
Read more →OSURStrategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizing across U.S. a
OraSure is actively pursuing a focused strategy designed to enhance revenue growth and profitability, with several product launches on the horizon. The company's diagnostics segment is poised for expansion, leveraging existing infrastructures and improving efficiency through operational transitions. Despite facing challenges, including pressure from Altai Capital regarding board decisions, OraSure aims for a strong market position as health funding stabilizes and testing volumes recover post-2025.
Read more →OSUROraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
OraSure Technologies, Inc. is responding to Altai Capital's demands for board representation, emphasizing its commitment to shareholder value and upcoming milestones in 2026. The company has engaged extensively with Altai but has faced rejection of settlement proposals. OraSure's Board has been refreshed with new independent directors to guide the company through this critical phase.
Read more →OSUR▲ +10%on this news
OraSure Announces Fourth Quarter 2025 Financial Results
OraSure Technologies reported its Q4 2025 financial results, achieving revenue of $26.8 million, which surpassed expectations. The company is optimistic about growth in 2026, driven by anticipated regulatory clearances and new product launches. OraSure's CEO highlighted the stability in key segments and the company's strategic investments to enhance value.
Read more →OSUROraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies has announced that its OraQuick HIV Self-Test has received licensing from Health Canada, making it the first oral HIV self-test available in Canada. The test allows individuals to determine their HIV status using a simple oral swab in just 20 minutes. This initiative aims to improve access to HIV testing and support public health efforts in combating the epidemic.
Read more →OSUROraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
OraSure Technologies, Inc. will hold its earnings conference call on February 25, 2026, at 5 p.m. ET to discuss its fourth quarter 2025 financial results and business developments. The call will be accessible via a webcast on the company's investor relations page, which will also archive the session afterward.
Read more →OSUROraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies has confirmed the receipt of director nominations from Altai Capital for the upcoming 2026 Annual Meeting of Stockholders. The nominations include Altai's founder, Rishi Bajaj. However, since interviewing Mr. Bajaj, OraSure's Board has appointed alternative candidates and has not engaged further with Altai. The Board has seen a significant refreshment with seven departures and three new independent members, aiming to enhance its oversight of growth and value creation.
Read more →OSUROraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies has submitted applications to the FDA for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, alongside its Colli-Pee™ urine collection device. These submissions aim to enhance accessibility and convenience in STI testing. The company anticipates significant market opportunities, although regulatory approvals and competition pose potential risks.
Read more →OSURInvestor Contact Media Contact Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications investorinfo orasure.com media orasure.com OraSure Submits CT NG Molecular Self-Test and Colli-Pee Urine Col
OraSure Technologies has submitted applications for FDA clearance of two new products: a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, and an at-home urine collection device called Colli-Pee. The rapid test aims to decentralize diagnostics by providing near-instant results in a convenient format. Additionally, the Colli-Pee device targets patients' preferences for private testing. These submissions are part of OraSure's strategy to expand its market presence and improve access to STI testing.
Read more →OSUROraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
OraSure Technologies has confirmed the intent of Altai Capital to nominate two candidates for election to its Board of Directors at the 2026 Annual Meeting. The company maintains a commitment to shareholder value and has engaged in dialogue with Altai, evaluating its founder, Rishi Bajaj, for board service. Despite not appointing him, OraSure has made efforts to enhance its Board and is actively pursuing innovation in diagnostics. The company remains well-positioned financially with substantial cash reserves and no debt as it strives for sustainable profitability.
Read more →OSUROraSure to Participate in Upcoming Investor Conference
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its participation in the upcoming Stephens Annual Investment Conference on November 19, which includes a Q&A session at 10 a.m. CT. The company will provide a live webcast and replay of the session on their investor relations website. OraSure focuses on decentralizing diagnostics, innovating in health technology, and improving access to healthcare through various products. This initiative indicates their commitment to maintaining transparent communication with shareholders and the market.
Read more →OSUR▼ -6.6%on this news
OraSure Announces Third Quarter 2025 Financial Results
OraSure Technologies reported a revenue of $27.1 million for Q3 2025, with optimism for growth in 2026 driven by diversification and new product launches. CEO Carrie Eglinton Manner emphasized the company's strategy to decentralize diagnostics and improve healthcare access. The company anticipates Q4 revenues between $25 million and $28 million, with minimal contributions from COVID-19 testing.
Read more →OSUROraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
OraSure Technologies, Inc. has scheduled its earnings conference call for November 5, 2025, at 5 p.m. ET to discuss third quarter financial results and business developments. The call will be accessible via a webcast on the company's investor relations page. An archived version will be available for one year post-call.
Read more →OSUROraSure Technologies Appoints Steven K. Boyd to its Board of Directors
OraSure Technologies has appointed Steven K. Boyd as a Class II director, enhancing its Board with significant capital markets expertise. This appointment is part of a broader strategy to refresh the Board, which has seen three new independent directors in three years. The company is focused on operational excellence and profitable growth, following a successful transformation.
Read more →OSUROraSure Announces Second Quarter 2025 Financial Results
OraSure Technologies, Inc. announced its financial results for Q2 2025, showing total net revenues decreased by 43% from the previous year primarily due to a significant decline in COVID-19 related revenues. While the company has launched new products and maintains a strong cash position, it reported substantial operating losses, raising concerns about its financial health. The guidance for Q3 suggests cautious optimism about potential revenue recovery.
Read more →OSUROraSure Appoints Anne Messing as Chief Commercial Officer
OraSure Technologies has appointed Anne Messing as Chief Commercial Officer. With over 25 years of experience in the healthcare sector, Messing will oversee Sales, Marketing, Strategic Alliances, and Product Management. Her previous roles include leadership positions at Becton Dickinson and other notable healthcare companies. The company anticipates her leadership will enhance its market position and drive growth.
Read more →OSUROraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. has scheduled its earnings call to discuss the second quarter 2025 financial results and recent business developments. The call is set for 5 p.m. ET on August 5, 2025, with a webcast available on the company's investor relations page. Interested participants can pre-register to ask questions during the call. The call will be archived for access on OraSure's website for approximately one year after the event.
Read more →OSUROraSure Launches Novel Blood Collection Device for Proteomic Research
OraSure Technologies has launched the HEMAcollect™PROTEIN blood collection tube, designed to preserve plasma proteins for up to seven days. This innovative product aims to enhance the efficiency of proteomic research by ensuring sample integrity and compatibility with various technologies. The launch reflects OraSure's commitment to improving research quality in fields such as oncology and neurology.
Read more →OSUROraSure Announces First Quarter 2025 Financial Results
OraSure Technologies, Inc. (NASDAQ: OSUR) reported its financial results for Q1 2025, showing a significant decrease in total net revenues, which fell 45% compared to the previous year. A notable decline in COVID-19 diagnostics revenue was a major contributor to the overall revenue drop. Despite these challenges, the company expressed confidence in its innovation roadmap and ongoing efforts to strengthen customer relationships. The CEO highlighted plans for multiple new product milestones in 2025, along with a recently authorized $40 million stock repurchase program.
Read more →OSUROraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th
OraSure Technologies, Inc. has announced an earnings conference call scheduled for May 7, 2025, at 5 p.m. ET to discuss its first quarter 2025 financial results. The call will be available via a webcast on the company's investor relations page, and registrants will receive specific access details via email. This conference call will cover business developments alongside the financial results.
Read more →OSUR▲ +6.4%on this news
OraSure Announces $40 Million Stock Repurchase Program
OraSure Technologies, Inc. has announced a $40 million stock repurchase program authorized by its Board of Directors. The program will be funded from the company's cash reserves and is set to occur over the next twenty-four months. Management will determine the timing and amount of repurchases, which can be modified or suspended at their discretion.
Read more →OSUR▲ +6.4%on this newsshared move
Investor Contact Jason Plagman VP, Investor Relations investorinfo orasure.com Media Contact Amy Koch Director, Corporate Communications media orasure.com OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM,
OraSure Technologies, Inc. has announced a $40 million stock repurchase program, authorized by its Board of Directors. The initiative will utilize the company’s cash reserves over the next two years. Management will have the discretion to determine the method and timing of the share repurchases. However, the program is subject to modification or suspension without prior notice. This move reflects the company's confidence in its financial position and future outlook.
Read more →OSUROraSure Reports Fourth Quarter 2024 Financial Results
OraSure Technologies, Inc. reported its financial results for Q4 2024, revealing a 51% decline in total net revenues compared to Q4 2023. Core revenue showed a more positive trend, increasing by 10% year-over-year. The company made significant strides in its strategic transformation, particularly by acquiring Sherlock Biosciences, which is expected to enhance its diagnostic capabilities. However, the report highlighted challenges, including a steep drop in COVID-19 related revenue and substantial operating losses.
Read more →OSUROraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th
OraSure Technologies, Inc. will announce its fourth quarter 2024 financial results and discuss key business developments during an earnings call scheduled for February 25, 2025. The call will be accessible via a live webcast on the company’s investor relations page, with an archive available afterward. This event highlights OraSure's commitment to transparency and engagement with stakeholders regarding its financial performance and strategic direction.
Read more →OSUROraSure to Present at the J.P Morgan Healthcare Conference
OraSure Technologies, Inc. (NASDAQ: OSUR) announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 16, 2025. During the event, members of the management team will present details regarding the company's advancements in point-of-need and home diagnostic tests. The presentation can be accessed via a live webcast on OraSure's investor relations website, reflecting the company's commitment to transparency and engagement with stakeholders.
Read more →OSUROraSure Technologies, Inc. 2 This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to OraSure Technologies, Inc
OraSure Technologies, Inc. has announced the acquisition of Sherlock Biosciences, aiming to enhance their portfolio with innovative molecular diagnostics. This move aligns with their strategy to improve healthcare access through point-of-need and self-testing solutions. However, the success of this acquisition hinges on several factors, including regulatory approvals and effective integration of Sherlock's operations. The transaction structure indicates significant considerations based on future product approvals, which may affect revenue streams in upcoming years.
Read more →OSUROraSure Technologies Acquires Sherlock Biosciences
OraSure Technologies, Inc. announced its acquisition of Sherlock Biosciences, enhancing its diagnostic solutions aimed at consumer healthcare. The acquisition features Sherlock's innovative molecular diagnostics platform, capable of delivering rapid results for sexually transmitted infections. The first product from this partnership will target Chlamydia Trachomatis and Neisseria Gonorrhoeae, pending regulatory approval. With an estimated market for these tests exceeding $1.5 billion, OraSure aims to leverage its existing infrastructure to drive future growth.
Read more →OSUROraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
OraSure Technologies, Inc. has received federal funding through the Rapid Response Partnership Vehicle to develop a rapid antigen test for the Marburg Virus Disease. This contract, with an initial value of approximately $7.5 million, aims to secure FDA 510(k) clearance for a lateral flow immunoassay intended for diagnosing individuals with MVD. The test could significantly enhance the response to Marburg virus outbreaks, which pose serious public health risks. This initiative highlights OraSure's commitment to addressing global health challenges in collaboration with government entities.
Read more →OSUROraSure Reports Q3 ’24 Revenue of $39.9 Million
OraSure Technologies reported its Q3 2024 financial results, revealing a significant decrease in total net revenues to $39.9 million, down 55% from the previous year. The company is transitioning its focus away from the declining Risk Assessment testing business towards diagnostics and sample management, which it sees as more promising growth areas. Despite the challenges, the company has received initial international orders for its OraQuick® HCV Self-test following WHO pre-qualification, and is planning to expand its operations into blood proteomics. Operating losses were reported, but a positive cash flow from operations was generated in Q3.
Read more →OSUROraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th
OraSure Technologies, Inc. plans to announce its third quarter 2024 financial results on November 6, 2024, during a conference call at 5 p.m. ET. The call will also cover certain business developments and will be accessible via a webcast on OraSure's investor relations page. Participants can pre-register to ask questions during the event. The company is noted for its role in providing rapid diagnostic tests and improving healthcare access globally.
Read more →OSUROraSure Technologies Elects Jack Kenny to the Board of Directors
OraSure Technologies, Inc. has appointed Jack Kenny to its Board of Directors, effective September 9, 2024. Kenny brings over 30 years of experience in the diagnostics industry, including leadership roles at Meridian Bioscience and Siemens Healthcare. His appointment expands OraSure's board to seven members, with expectations that he will contribute to the company's growth and profitability. This move is part of OraSure's ongoing efforts to strengthen its management team as it seeks to enhance its core operations.
Read more →OSUROraSure Reports Q2 ’24 Revenue of $54.3 Million
OraSure Technologies, Inc. (NASDAQ: OSUR) reported its Q2 2024 financial results, revealing a total net revenue of $54.3 million, a 36% decline from the previous year. The company experienced a notable increase in gross margins due to operational efficiencies, but core revenues also decreased by 7% amid exiting certain areas of business. On a positive note, OraSure achieved WHO pre-qualification for its HCV self-test and continues to see momentum in its syphilis testing products. The company maintains a strong balance sheet, which offers flexibility for its future initiatives.
Read more →OSUROraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th
OraSure Technologies, Inc. has announced their upcoming earnings conference call for the second quarter of 2024, scheduled for 5 p.m. ET on August 6, 2024. During this call, the company will discuss financial results along with various business developments. The conference call will be accessible via webcast, which will also be archived on their investor relations page for future viewing. Interested participants can pre-register to ask questions during the call.
Read more →OSUROraSure Technologies Supports National HIV Testing Day
OraSure Technologies announced its support for National HIV Testing Day, highlighting its initiative to encourage widespread HIV testing in the U.S. The company is distributing its OraQuick HIV Self-Test kits through various programs, including a collaboration with the CDC to provide a million free kits over five years. The updated self-test, available since 2012, now features improved sustainability and educational materials to enhance user experience. This effort aims to empower individuals, especially in high-risk communities, to learn their HIV status and connect to care.
Read more →OSUROraSure Reports Q1 ’24 Revenue of $54.1 Million
OraSure Technologies reported a 65% decline in total net revenue for Q1 2024, totaling $54.1 million, in part due to a significant drop in COVID-19 revenue. The company is implementing restructuring initiatives expected to yield $15 million in annual savings, with a goal to reach cash flow break-even by the end of 2024. Despite the current challenges, OraSure remains focused on partnerships and solidifying its core business as it transitions away from less profitable segments.
Read more →OSUROraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
OraSure Technologies, Inc. (NASDAQ: OSUR) is scheduled to announce its first quarter 2024 financial results during a conference call on May 8, 2024, at 4:45 p.m. ET. Investors can access the call via a webcast on the company's website, where it will be archived for approximately 90 days. This call aims to highlight both financial performance and key business developments, emphasizing the company's commitment to healthcare innovation.
Read more →OSUROraSure Reports Q4 ‘23 Revenue of $75.9 Million
OraSure Technologies, Inc. reported Q4 2023 revenue of $75.9 million, a 38% decrease compared to Q4 2022 due to significant drops in COVID-19 related sales. Despite this downturn, the company's core business, primarily driven by HIV sales, showed slight year-over-year growth. OraSure also increased its cash balance to $290.4 million, supported by operational improvements and the receipt of government funding. The firm aims to achieve operating cash flow break-even for its core business by the end of 2024 through strategic partnerships and innovations.
Read more →OSUR▼ -5%on this news
OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th
OraSure Technologies, Inc. (NASDAQ: OSUR) will hold its earnings conference call for the fourth quarter of 2023 on February 27, 2024, at 5 p.m. ET. The call will cover financial results and business developments, with a live webcast accessible through the company's investor relations page. OraSure aims to provide actionable health insights and offers a range of diagnostic and sample management solutions through its subsidiaries.
Read more →OSUROraSure Technologies, Inc. 2 This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to products, product develop
OraSure Technologies, Inc. has entered into a strategic partnership with KKR Sapphiros, L.P., gaining exclusive distribution rights to a portfolio of innovative products. This collaboration includes a $30 million investment by OraSure to lead Sapphiros' Series B funding round, aimed at accelerating product development in diagnostics and sample management solutions. The partnership is expected to contribute significantly to revenue and improve healthcare outcomes through the introduction of new diagnostic tests and self-collection devices. The initial product launch is anticipated for late 2024, with additional products expected in the following years, subject to regulatory approvals.
Read more →OSUROraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company
OraSure Technologies, Inc. has announced a strategic partnership and investment in Sapphiros, a consumer diagnostics company. This agreement provides OraSure with exclusive distribution rights to key products from Sapphiros' innovative development pipeline. Initial product distribution is expected to begin in 2024 and will enhance OraSure's core revenue growth starting in 2025. The collaboration will focus on expanding access to affordable diagnostic tests, addressing unmet needs in the consumer diagnostics market.
Read more →OSUROraSure to Participate in Upcoming Investor Conferences
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its participation in two upcoming investor conferences: the Stephens Annual Investment Conference on November 15 and the Evercore ISI Annual HealthCONx Conference on November 28. Both conferences will feature Q&A sessions, allowing OraSure to interact with investors. Webcasts of the sessions will be streamed live and made available for approximately 90 days on the company's investor relations website.
Read more →OSUROraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year
OraSure Technologies, Inc. reported its Q3 2023 financial results, revealing a total net revenue of $89.2 million, a 23% decrease from Q3 2022. However, core revenue, excluding COVID-19 products, grew by 7% year-over-year, indicating strong performance in its diagnostic and molecular product segments. The company's cash balance reached $224.9 million, bolstered by operational efficiencies and a new contract with the U.S. government. Despite the decline in overall revenues, OraSure's operating income increased significantly, reflecting its focus on disciplined execution and cost management.
Read more →OSUROraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th
OraSure Technologies, Inc. has announced a date for its earnings conference call to discuss the financial results for the third quarter of 2023. The call is scheduled for November 7, 2023, at 5:00 pm ET and will cover key business developments. Investors can access the call via a webcast available on the company's investor relations page.
Read more →OSUROraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year
OraSure Technologies, Inc. reported its financial results for Q2 2023, revealing a total net revenue of $85.4 million, a 6% increase from the previous year. Core revenue, excluding COVID-19 revenues, grew by 3% year-over-year and 4% sequentially. The company anticipates achieving break-even cash flow from operations in its core business by the end of 2024. Despite a significant decrease in InteliSwab® test revenue in the recent quarter, the overall financial health remains robust with a cash balance increase to $185.9 million.
Read more →OSUROraSure to Announce Second Quarter 2023 Financial Results and Host Earnings Call on August 3rd
OraSure Technologies, Inc. has announced that it will hold its regular earnings conference call on August 3, 2023, at 5:00 pm ET. The call will cover the financial results for the second quarter of 2023 along with some business developments. Investors can access the call via a webcast and pre-register for participation. The archived version will be available for approximately 90 days after the call.
Read more →OSUROraSure Technologies Elects Robert McMahon to the Board of Directors
OraSure Technologies has announced the election of Robert W. McMahon to its Board of Directors, effective July 31, 2023. McMahon, who currently serves as the Senior Vice President and Chief Financial Officer at Agilent Technologies, has over 30 years of senior finance experience in the healthcare sector. His expertise in business growth and financial management is anticipated to add significant value to OraSure as the company continues its transformation journey. The board now consists of seven members, emphasizing a commitment to strong leadership during this critical phase.
Read more →OSURInvestor Contact: Scott Gleason SVP Investor Relations & Corp. Communications (484) 425-0588 sgleason@orasure.com Media Contact: Amy Koch Director, Corporate Communications (484) 523-1815 media@orasure.com OraSure Report
OraSure Technologies, Inc. reported record revenue of $155 million for Q1 2023, marking a 129% increase from the same quarter last year. The company is focusing on core growth by consolidating production and enhancing operational efficiencies, alongside signing new partnerships in cancer diagnostics and women's health. Despite the substantial growth in revenue, they noted a decline in molecular product sales year-over-year. The management expects challenges as COVID-19 related revenues taper, but anticipates continued improvement in cash flow and profitability.
Read more →OSUROraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth
OraSure Technologies, Inc. reported record revenues of $155 million for the first quarter of 2023, representing a 129% increase compared to the same quarter last year. The company has focused on its core growth by signing three new molecular partnerships and has successfully improved its gross margins amidst operational challenges. Additionally, OraSure is beginning to taper its InteliSwab® test production in response to decreased COVID-19 demand, while also consolidating and streamlining its manufacturing processes. Overall, the company's financial position remains strong, with significant cash reserves contributed by increased test volumes.
Read more →OSURInvestor Contact: Scott Gleason SVP investor Relations & Corporate Communications (484) 425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Manager Corporate Communications (484) 523-1815 media@orasure.com OraSure
OraSure Technologies, Inc. reported record revenue of $123.1 million for Q4 2022, a 94% increase from the previous year. The company expanded its InteliSwab revenue with new government contracts, while signing a deal with Quest Diagnostics. Despite this growth, Core Molecular Solutions experienced a 32% decline in revenues, attributed to customer destocking. The company has initiated a restructuring aimed at reducing operating expenses by $15 million and aims for cash flow breakeven by the end of 2024.
Read more →OSUROraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability
OraSure Technologies reported record revenue of $123.1 million for Q4 2022, a 94% increase compared to the same period the previous year. The company highlighted successful restructuring efforts aimed at reducing operational costs by $15 million and achieving cash flow breakeven by the end of 2024. Despite significant growth in demand for the InteliSwab® product, there were declines noted in Core Molecular Solutions revenue and COVID-19 kits, indicating some challenges ahead. The management remains optimistic about future growth driven by strategic partnerships and innovation.
Read more →OSUROraSure Technologies Continues its Dedication to Ending the HIV Epidemic
BETHLEHEM, Pa., Dec. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in the fight against HIV, will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day. World AIDS Day is commemorated annually on Dece
Read more →OSUROraSure Technologies to Present at Stephens Annual Investment Conference
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will par
Read more →OSURInvestor Contact: Scott Gleason SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure Reports 3Q2
OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year InteliSwab revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity Company wins new contracts for COVID-19 testing along with retail wins includin
Read more →OSUROraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity Company wins new contracts for COVID-19 testing along with retail wins including availability on Amazon.com Q3 GAAP EPS of $0.07 and non-GAAP EPS of $0.13 Com
Read more →OSUROraSure Technologies Receives General Clearance for its ORAcollect •Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care
Read more →OSUR▲ +9.8%on this news
OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test
BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research and Development Authority (BARDA) h
Read more →OSUROraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention
BETHLEHEM, Pa., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company has been selected to provide its OraQuick® In-Home HIV t
Read more →OSUROraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today a new collaboration between Diversigen, Inc., a subsidiary of OraSure Tec
Read more →OSUROraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
InteliSwab® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production InteliSwab® gross margins improve sequentially by over 2,000 basis points GAAP gross margin of 34.4%, a decrease of 200 basis points sequentially; non-GAAP gross margins impro
Read more →OSURInvestor Contact: Scott Gleason SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure Reports 2Q2
OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year InteliSwab revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production InteliSwab gross margins improve sequentially by over 2,000 basis points GAAP gross margin of 3
Read more →OSUROraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, August 9, 20
Read more →OSUROraSure’s Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack
BETHLEHEM, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its ongoing commitment to fight the hepatitis C epidemic. July 28 is comme
Read more →OSUROraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its OMNIgene®•GUT DNA and RNA product (OMR-205) is now available to g
Read more →OSUR▼ -9%on this news
OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BETHLEHEM, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that on June 4, 2022, OraSure’s Board of Directors granted Carrie Eglinton
Read more →OSURCarrie Eglinton Manner Appointed Chief Executive Officer of OraSure
Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success BETHLEHEM, Pa., May 23, 2022 (GLOBE NEWSWIRE) OraSure Technologies,
Read more →OSUR▼ -6.6%on this news
OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue
InteliSwab® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production Non-COVID molecular kits increase 42% year-over-year demonstrating continued strong growth Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHE
Read more →OSUR▼ -6.6%on this news
Investor Contact: Scott Gleason Interim CFO, SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSur
OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue InteliSwab revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production Non-COVID molecular kits increase 42% year-over-year demonstrati
Read more →OSUROraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, May 10, 2022. May
Read more →OSUROraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples
BETHLEHEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been gra
Read more →OSUROraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its’ Diversigen subsidiary has launched a new service to provide met
Read more →OSUROraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role
Board Continues Search for Permanent CEO Evaluation of Strategic Alternatives Ongoing BETHLEHEM, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome l
Read more →OSUROraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab Production Scales Up
Total 2021 revenue of $233.7 million, up 36% year-over year InteliSwab® receives emergency use authorization expansion and demonstrates accurate detection of Omicron variant InteliSwab® revenue of $14.7 million in Q4, up 92% sequentially Management to Host Analyst/Investor Cal
Read more →OSURInvestor Contact: Scott Gleason Interim CFO SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure
OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab Production Scales Up Total 2021 revenue of $233.7 million, up 36% year-over year InteliSwab receives emergency use authorization expansion and demonstrates accurate detection of Omicron variant InteliSwab r
Read more →OSUROraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2
Read more →OSUROraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe
BETHLEHEM, Pa., Jan. 25, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has launched its OraQuick® HIV Self-Test, an oral swab in-home te
Read more →OSUROraSure Technologies Announces Actions to Enhance Stockholder Value
Provides Preliminary 4Q21 Financial Outlook Commences Review of Strategic Alternatives Announces Transition of CEO and Organizational Changes BETHLEHEM, Pa., Jan. 05, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home
Read more →OSUROraSure Technologies Announces 2022 Annual Meeting Date
BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022. The record date for the Meeting will be Mar
Read more →OSUROraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus
BETHLEHEM, Pa., Nov. 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in the fight against HIV, today announced its plans for World AIDS Day. Commemorated annually on December 1, the U.S. Government's theme for this year’s World AIDS Day is
Read more →OSUROraSure Technologies to Present at Upcoming Investor Conferences
BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will p
Read more →OSUROraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary
BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is r
Read more →OSURInvestor Contact: Scott Gleason Interim CFO & SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSu
OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary BETHLEHEM, PA., Nov. 9, 2021 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point
Read more →OSUROraSure Technologies Appoints Two New Members to the Board of Directors
New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience BETHLEHEM, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-c
Read more →OSUROraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22
Third quarter revenue of $53.9 million grew 12% year-over-year; excluding COVID-19 product revenues, revenues for the quarter grew 37% from the prior year, demonstrating strong growth OraSure signs three major U.S. government contracts providing $205 million in government Inteli
Read more →OSUROraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November 3, 202
Read more →OSURInvestor Contact: Scott Gleason SVP Investor Relations & Corporate Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure Awarded
OraSure Awarded $109 Million Contract from U.S. Department of Defense to Ramp Manufacturing of InteliSwab COVID-19 Rapid Test Agreement Ensures OraSure Will Have Sufficient Capacity to Meet Market Need for Rapid Antigen Tests and Ensure Future Preparedness BETHLEHEM, PA., Octo
Read more →OSUROraSure Awarded $109 Million Contract from U.S. Department of Defense to Ramp Manufacturing of InteliSwab™ COVID-19 Rapid Test
BETHLEHEM, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has been awarded a $109 million contract from the U.S. Department
Read more →OSUROraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
BETHLEHEM, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority (BARDA), part
Read more →OSUROraSure Receives $205 Million Procurement Contract for InteliSwab™ from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Response
BETHLEHEM, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Defense Logistics Agency has awarded the Company a procurement c
Read more →OSURForward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees
Investor Presentation August 2021 EXHIBIT 99.1 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future pe
Read more →OSUROraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan
BETHLEHEM, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care testing and sample collection technologies, announced that Chief Financial Officer Roberto Cuca has resigned from the Company effective September 17, 202
Read more →OSURInvestor Contact: Scott Gleason Interim CFO & SVP Investor Relations & Corporate Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com O
OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO BETHLEHEM, PA., September 2, 2021 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a glob
Read more →OSURInvestor Contact: Scott Gleason SVP Investor Relations & Corporate Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-353-1815 media@orasure.com OraSure Technol
OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business Excluding COVID-19 product revenues, revenues for the second quarter grew 122% YoY and 48% sequentially as the Company's core business began to return to pre-pandemic revenue lev
Read more →OSUROraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business
Excluding COVID-19 product revenues, revenues for the second quarter grew 122% YoY and 48% sequentially as the Company’s core business began to return to pre-pandemic revenue levels Company received three Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administra
Read more →OSUROraSure Technologies, Inc. to Hold 2021 Second Quarter Earnings Conference Call Tuesday, August 3, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., July 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, August 3, 2021.
Read more →OSUROraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference
BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, wi
Read more →OSUROraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing
BETHLEHEM, Pa. and HUNTERSVILLE, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it is collaborating with the Will Rodgers Liver Health Foundation to increase awareness around the role Hepatitis C (HCV) plays in chronic liver
Read more →OSUROraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescription (OTC), Professional and Prescription Use
BETHLEHEM, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 rapid antigen tests, which the Company is branding
Read more →OSUROraSure Technologies to Present at the Jefferies Virtual Healthcare Conference
BETHLEHEM, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will pa
Read more →OSUROraSure Technologies to Present at the UBS Global Healthcare Virtual Conference
BETHLEHEM, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will pa
Read more →OSUROraSure Technologies Appoints Scott Gleason As Senior Vice President Investor Relations and Corporate Communications
BETHLEHEM, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Scott Gleason has been appointed Senior Vic
Read more →OSUROraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 18, 2021
BETHLEHEM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern (7:00 a.m. Pacific) on Tuesday, May
Read more →OSURInvestor Contact: Sam Martin Argot Partners 212-600-1902 orasure@argotpartners.com Media Contact Jeanne Mell OraSure Technologies 484-353-1575 media@orasure.com OraSure Technologies, Inc. Announces First Quarter 2021 Fin
OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing EUA Applicat
Read more →OSUROraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update
First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing EUA Application Submitted in Q1 to FDA for COVID-19 Rapid Antigen Test for Both Prescription Home Use and Profession
Read more →OSUROraSure Technologies to Hold 2021 First Quarter Earnings Conference Call Wednesday, May 5, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., April 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, May 5, 2021.
Read more →OSUROraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emergency Use Authorization
BETHLEHEM, Pa., March 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its COVID-19 rapid antigen test for both Presc
Read more →OSURInvestor contact: Sam Martin Argot Partners 212-600-1902 orasure@argotpartners.com Media contact: Jeanne Mell OraSure Technologies 484-353-1575 media@orasure.com OraSure Technologies, Inc. Announces 2020 Full-Year and Fo
OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular
Read more →OSUROraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update
Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing COVID-19 Rapid Antigen Test clinical trials complete; OraSure plans to submit both a Prescription Self-Test an
Read more →OSUROraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO,
Read more →OSUROraSure Subsidiary DNA Genotek’s OMNIgene ORAL Included in EUA Granted to Ambry Genetics for Use in COVID-19 RT-PCR Saliva Test
BETHLEHEM, Pa., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its OMNIgene®·ORAL (OM-505) saliva collection k
Read more →OSUROraSure Subsidiary DNA Genotek’s OMNIgene ORAL Saliva Collection Device Receives Health Canada Authorization for use in COVID-19 Testing
OTTAWA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its OMNIgene®·ORAL (OME-505) saliva collection device,
Read more →OSUROraSure’s OMNIgene ORAL Saliva Collection Kit Selected by Chronomics for Use in UK Government “Test to Release for International Travel” COVID-19 Testing Program
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Chronomics Limited has selected the OMNIge
Read more →OSUROraSure’s Oragene •Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencing Platform
BETHLEHEM, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Oragene®•Dx (OGD-610) saliva collectio
Read more →OSUROraSure Technologies Announces 2021 Annual Meeting Date
BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 18, 2021. The record date for the Meeting will be Mar
Read more →OSUROraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO,
Read more →OSUROraSure’s OMNIgene ORAL Device Included in EUA Amendment Granted to 3B BlackBio Biotech India for SARS-CoV-2 Test
OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM/OME-505) collection device
Read more →OSURInvestor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 orasure@argotpartners.com media@orasure.com OraSure Technologies Provides Update on Its Emergen
Investor Contact:Media Contact: Sam MartinJeanne Mell Argot PartnersVP Corporate Communications 212-600-1902484-353-1575 orasure@argotpartners.commedia@orasure.com OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Flu
Read more →OSUROraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test
BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration (FDA) has requested additional information as part o
Read more →OSUROraSure Technologies to Present at the 2020 Evercore ISI HealthCONx Conference
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 2020
Read more →OSUROraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Closing Bell
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tuesday, Dec. 1st, OraSure will ring the closing bell for the NASDAQ Stock Market, in a virt
Read more →OSUROraSure Technologies to Present at the Stephens Annual Investment Conference 2020
BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO,
Read more →OSUROraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments
Net Third Quarter Revenues of $48.0 Million Increased 33% Year-Over-Year, Driven by $18.4 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing Company Has Submitted EUA Application For Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test Management to H
Read more →OSURInvestor contact: Media contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 orasure@argotpartners.com media@orasure.com OraSure Technologies, Inc. Announces Third Quarter
Investor contact: Media contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 orasure@argotpartners.com media@orasure.com OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19
Read more →OSUROraSure’s DNA Genotek Subsidiary Receives FDA Emergency Use Authorization for its ORAcollect RNA Saliva Collection Device for SARS CoV-2
BETHLEHEM, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergen
Read more →OSUROraSure Technologies to Hold 2020 Third Quarter Earnings Conference Call Wednesday, November 4, 2020, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November 4, 202
Read more →OSUROraSure’s OMNIgene ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2
BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergen
Read more →OSUROraSure’s ORAcollect RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test
BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) saliva colle
Read more →OSUROraSure’s ORAcollect RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test
BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection d
Read more →OSUROraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs
BETHLEHEM, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three and six mon
Read more →OSURInvestor contact: Sam Martin Argot Partners 212-600-1902 orasure@argotpartners.com Media contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com OraSure Technologies, Inc. Announces 2020 Second Qu
OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs BETHLEHEM, PA, August 5, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices
Read more →OSUROraSure’s OMNIgene ORAL Device Included in EUA Granted to Clinical Reference Laboratory for Self-Collected SARS-CoV-2 Saliva Test
BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM-505) saliva collect
Read more →OSUROraSure Technologies to Hold Second Quarter 2020 Earnings Conference Call on August 5th, 2020
2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET BETHLEHEM, Pa., July 22, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 second quarter financial results and
Read more →OSUROraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics
OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-h
Read more →OSUROraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples
BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the
Read more →OSUROraSure’s Oragene •Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 test
OTTAWA, June 08, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today that Phosphorus Diagnostics, a leader in diagnostic and
Read more →OSUROraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock
BETHLEHEM, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option to purchase an additional 1,200,000 shares of its common stock in connection with the Com
Read more →OSUROraSure Technologies, Inc. Prices Underwritten Offering of Common Stock
BETHLEHEM, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the pricing of an underwritten offering of 8,000,000 shares of its common stock at a price of $11.00 per share. After the underwriting discount
Read more →OSURInvestor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 OraSure@argotpartners.com media@orasure.com OraSure Technologies, Inc. Prices Underwritten Offe
Investor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 OraSure@argotpartners.com media@orasure.com OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock BETHLEHEM, Pa., June 2, 2020 (Gl
Read more →OSUROraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock
BETHLEHEM, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock. J.P. Morgan Securities LLC, Citigroup Global Markets
Read more →OSURInvestor Contact: Sam Martin Argot Partners 212-600-1902 orasure@argotpartners.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com
ORASURE TECHNOLOGIES APPOINTS LELIO MARMORA TO BOARD OF DIRECTORS BETHLEHEM, PA, May 29, 2020 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced
Read more →OSUROraSure Technologies Appoints Lelio Marmora to Board of Directors
BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of Lelio Marmora as a member of
Read more →OSUROraSure Technologies, Inc. Announces Purchase of UrSure, Inc.
BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, today announced that it has entered into a
Read more →OSUROraSure Technologies to Present at the Jefferies 2020 Healthcare Conference
BETHLEHEM, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, Ph.D., President an
Read more →OSUROraSure’s OMNIgene ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test
OTTAWA, May 22, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, (NASDAQ: OSUR), announced today that its OMNIgene®·ORAL saliva collectio
Read more →OSUROraSure Technologies to Present at the UBS Virtual Global Healthcare Conference
BETHLEHEM, Pa., May 15, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS V
Read more →OSUROraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 19, 2020
BETHLEHEM, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2020 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 19, 202
Read more →OSUROraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
All Microbiome Services to be Unified under the Diversigen Brand BETHLEHEM, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services,
Read more →OSUROraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update
BETHLEHEM, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced its financial results for the three months ended
Read more →OSURs: Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2020 F
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update BETHLEHEM, PA -
Read more →OSUROraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit Lead
BETHLEHEM, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Lisa Nibauer has been appointed Executive V
Read more →OSURInvestor Contact: Roberto Cuca Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com ORASURE TECHNOLOGIES APPOINTS LISA NIBAUE
ORASURE TECHNOLOGIES APPOINTS LISA NIBAUER AS INFECTIOUS DISEASE BUSINESS UNIT LEAD Board Change Also Announced BETHLEHEM, PA, May 5, 2020 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of- care diagnostic tests, specimen collection devices, and microbiome labo
Read more →OSUROraSure Technologies Earnings Conference Call Invitation
2020 First Quarter Earnings Conference Call Wednesday, May 6, 2020, 5:00 p.m. ET BETHLEHEM, Pa., April 09, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 first quarter financial results, update
Read more →OSURInvestor Contact: Robert Cuca Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com ORASURE TECHNOLOGIES APPOINTS DAVID J. SHU
ORASURE TECHNOLOGIES APPOINTS DAVID J. SHULKIN, M.D. TO BOARD OF DIRECTORS -- Other Board Changes Also Announced -- BETHLEHEM, PA, April 8, 2020 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome
Read more →OSUROraSure Technologies Appoints David J. Shulkin, M.D. to Board of Directors
BETHLEHEM, Pa., April 08, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of David J. Shulkin, M.D., as
Read more →OSUROraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test
BETHLEHEM, Pa., April 06, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $710,310 contract from th
Read more →OSURs: Roberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com OraSure Technologies Receives BARDA Contract for Rapid O
OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test BETHLEHEM, PA, April 6, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microb
Read more →OSUROraSure Technologies to Present at the Raymond James 41st Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raym
Read more →OSUROraSure Announces 2019 Full Year and Fourth Quarter Financial Results
BETHLEHEM, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced its financial results for the three months and y
Read more →OSURs: Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 F
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Full Year and Fourth Quarter Financial Results BETHLEHEM, PA - February 19, 2
Read more →OSUROraSure Technologies to Present at the 38th Annual J.P. Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 38TH
Read more →OSUROraSure Technologies Announces 2020 Annual Meeting Date
BETHLEHEM, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2020 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 19, 2020. The record date for the Meeting will be M
Read more →OSUROraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Opening Bell
BETHLEHEM, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Monday, Dec. 2nd, OraSure will ring the opening bell for the NASDAQ Stock Market. The bell
Read more →OSUROraSure Technologies to Present at the Piper Jaffray 31st Annual Healthcare Conference
BETHLEHEM, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Pipe
Read more →OSUROraSure Announces 2019 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the three and nine months ended September 30, 2019. Financial and Bu
Read more →OSUROraSure Technologies, Inc. Announces Purchase of Diversigen
BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding eq
Read more →OSUROraSure Technologies to Present at Stephens 2019 Nashville Investment Conference
BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, and Mr. Roberto Cuca, Chief Financial Officer will
Read more →OSURRoberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Th
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Third Quarter Financial Results BETHLEHEM, PA - November 6, 2019 - (Globe New
Read more →OSUROraSure Technologies Announces Support for New Federal Oral Fluid Drug Testing Guidelines
BETHLEHEM, Pa., Oct. 28, 2019 (GLOBE NEWSWIRE) -- The Substance Abuse and Mental Health Services Administration (SAMHSA) has published new guidelines, permitting oral fluid drug testing in federally regulated markets. SAMHSA is the agency within the U.S. Department of Health and
Read more →OSUROraSure Announces Sale of Cryosurgical Systems Business
BETHLEHEM, Pa., Aug. 19, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced the sale of its cryosurgical systems business to CryoConcepts, LP for an aggregate purchase pric
Read more →OSURInvestor Contact: Roberto Cuca Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com OraSure Announces Sale of Cryosurgical Sy
OraSure Announces Sale of Cryosurgical Systems Business BETHLEHEM, PA, August 19, 2019 - OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced the sale of its cryosurgical systems business to CryoCon
Read more →OSURInvestor Contact: Robert Cuca Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com
ORASURE TECHNOLOGIES APPOINTS JAMES A. DATIN TO ITS BOARD OF DIRECTORS BETHLEHEM, PA, August 14, 2019 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of James A. Datin, as a
Read more →OSUROrasure Technologies Appoints James a. Datin to Its Board of Directors
BETHLEHEM, PA, Aug. 14, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of James A. Datin, as a member of the Company’s Board of Directors. Mr. Datin w
Read more →OSURRoberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Se
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Second Quarter Financial Results BETHLEHEM, PA - August 6, 2019 - (Globe News
Read more →OSUROraSure Announces 2019 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the three and six months ended June 30, 2019. “Second quarter revenu
Read more →OSUROrasure Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference
BETHLEHEM, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 39th
Read more →OSUROraSure Technologies and Others Join Forces for HIV Testing Day
BETHLEHEM, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- National HIV Testing Day will be commemorated on June 27 across the nation with efforts to raise awareness of HIV and encourage people to get tested and know their HIV status. OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in
Read more →OSUROrasure Technologies to Present at Raymond James 2019 Life Sciences and MedTech Conference
BETHLEHEM, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Mr. Roberto Cuca, Chief Financial Officer, will speak to the investment community at the R
Read more →OSUROraSure Technologies to Present at Jefferies 2019 Healthcare Conference
BETHLEHEM, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Jeffe
Read more →OSUROraSure Technologies to Present at UBS Global Healthcare Conference
BETHLEHEM, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS G
Read more →OSUROraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 21, 2019
BETHLEHEM, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2019 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 21, 201
Read more →OSURRoberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 Fi
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2019 First Quarter Financial Results BETHLEHEM, PA - May 8, 2019 - (Globe Newswire
Read more →OSUROraSure Announces 2019 First Quarter Financial Results
BETHLEHEM, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the quarter ended March 31, 2019. “Our first quarter 2019 performance
Read more →OSUROraSure Technologies to Present at the Raymond James 40th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raym
Read more →OSUROraSure Announces 2018 Full Year and Fourth Quarter Financial Results
BETHLEHEM, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the full year and fourth quarter of 2018. Financial Highlights Net
Read more →OSURRoberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2018 Fu
Roberto Cuca Jeanne Mell Chief Financial Officer 610-882-1820 VP Corporate Communications 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Announces 2018 Full Year and Fourth Quarter Financial Results BETHLEHEM, PA - February 6, 20
Read more →OSUROraSure Technologies, Inc. Announces Two Acquisitions and Reaffirms Fourth Quarter 2018 Guidance
CoreBiome leverages OraSure’s leadership position in microbiome sample collection with end-to-end laboratory services for sample processing, sequencing, and bioinformatics Novosanis’ urine collection technology expands molecular collection portfolio and advances OraSure’s expert
Read more →OSURRoberto Cuca Jeanne Mell Chief Financial Officer VP Corporate Communications 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Technologies, Inc
Roberto Cuca Jeanne Mell Chief Financial Officer VP Corporate Communications 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Technologies, Inc. Announces Two Acquisitions and Reaffirms Fourth Quarter 2018 Guidance Cor
Read more →OSUROraSure Technologies to Present at the 37th Annual J.P. Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 37TH
Read more →OSUROraSure Technologies, Inc.: Updated Release to Clarify Timing of Presentation
BETHLEHEM, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 37TH
Read more →OSUROraSure Technologies Announces 2019 Annual Meeting Date
BETHLEHEM, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2019 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 21, 2019. This will be a completely virtual meeting,
Read more →OSUROraSure Technologies to Ring NASDAQ Stock Market Opening Bell in Honor of World AIDS Day
BETHLEHEM, Pa., Nov. 29, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, Ph.D., President and CEO, will ring the NASDAQ stock market opening bell
Read more →OSUROraSure Technologies to Present at the 30th Annual Piper Jaffray Healthcare Conference
BETHLEHEM, Pa., Nov. 21, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the 3
Read more →OSUROraSure Technologies to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum
BETHLEHEM, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the C
Read more →OSURRoberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 Third Quarter Financial Results BETHLEHEM, PA
Roberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 Third Quarter Financial Results BETHLEHEM, PA - November 7, 2018 - (Globe Newswire) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnosti
Read more →OSUROraSure Announces 2018 Third Quarter Financial Results
BETHLEHEM, PA., Nov. 07, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the three and nine months ended September 30, 2018. Financial Highli
Read more →OSUROraSure Technologies to Present at the Cantor Global Healthcare Conference
BETHLEHEM, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the
Read more →OSUROraSure Technologies to Present at the CL King 16th Annual Best Ideas Conference
BETHLEHEM, Pa., Sept. 06, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, President and CEO, will speak to the investment community at the CL King
Read more →OSURRoberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 Second Quarter Financial Results BETHLEHEM, PA
Roberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 Second Quarter Financial Results BETHLEHEM, PA - August 8, 2018 - (Globe Newswire) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic
Read more →OSUROraSure Announces 2018 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 08, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2018. Financial
Read more →OSUROraSure Technologies, Inc. Appoints Vice President, Corporate Communications
BETHLEHEM, Pa., July 23, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostics and specimen collection devices, today announced that Jeanne Mell has been appointed as the Company’s new Vice President, Corporate Communications. Ms
Read more →OSUROraSure Technologies to Present at Jefferies Global Healthcare Conference
BETHLEHEM, Pa., May 30, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, President and CEO, will speak to the investment community at Jefferies Glob
Read more →OSUROraSure Technologies to Present at the UBS Global Healthcare Conference
BETHLEHEM, Pa., May 14, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, President and CEO, will speak to the investment community at the UBS Global
Read more →OSURShauna White Corporate Marketing Manager 484-353-1575 media@orasure.com www.orasure.com OraSure Technologies Appoints New Chief Financial Officer BETHLEHEM, PA .
Shauna White Corporate Marketing Manager 484-353-1575 media@orasure.com www.orasure.com OraSure Technologies Appoints New Chief Financial Officer BETHLEHEM, PA. - May 4, 2018 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen co
Read more →OSUROraSure Technologies Appoints New Chief Financial Officer
BETHLEHEM, Pa., May 04, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Roberto Cuca has been appointed as the Company’s new Chief Financial Officer, effective as o
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 First Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2018 First Quarter Financial Results BETHLEHEM, PA - May 2, 2018 - (Globe Newswire) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic
Read more →OSUROraSure Announces 2018 First Quarter Financial Results
BETHLEHEM, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the quarter ended March 31, 2018. Financial Highlights C
Read more →OSUROraSure Technologies to Hold Virtual Annual Meeting of Stockholders
BETHLEHEM, Pa., May 01, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), announced that its 2018 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tue
Read more →OSUROraSure Technologies Appoints New Senior Vice President, Business Development
BETHLEHEM, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that David Rappaport has been appointed as the Company’s new Senior Vice President, Business De
Read more →OSUROraSure Technologies to Present at the Raymond James 39th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 26, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymon
Read more →OSUROraSure Technologies to Present at the LEERINK 7th Annual Global Healthcare Conference
BETHLEHEM, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the LEERIN
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Record 2017 Fourth Quarter and Full-Year Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Record 2017 Fourth Quarter and Full-Year Financial Results BETHLEHEM, PA February 7, 2018 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in poin
Read more →OSUROraSure Announces Record 2017 Fourth Quarter and Full-Year Financial Results
BETHLEHEM, Pa., Feb. 07, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the fourth quarter and full-year ended December 31, 2017.
Read more →OSUROraSure Technologies Appoints Aradhana Sarin, M.D. to Board of Directors
BETHLEHEM, Pa., Feb. 02, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of Dr. Aradhana Sarin, as a member of the Company's Board of Directors. Dr. Sari
Read more →OSUR: Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 investorinfo@orasure.com media@orasure.com ORASURE TECHNOLOGIES APPOINTS ARADHANA SARIN, M.D. T
Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 investorinfo@orasure.com media@orasure.com ORASURE TECHNOLOGIES APPOINTS ARADHANA SARIN, M.D. TO BOARD OF DIRECTORS PA. February 2, 2018 OraSure Technologies, Inc. (N
Read more →OSUROraSure Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 05, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 36TH A
Read more →OSURJack E. Jerrett Senior Vice President, General Counsel and Secretary (610) 882-1820 jjerrett@orasure.com www.orasure.com OraSure Technologies Announces Management Succession Plan - Company Also Increases
Senior Vice President, General Counsel and Secretary jjerrett@orasure.com OraSure Technologies Announces Management Succession Plan - Company Also Increases Revenue Forecast for Q4 2017 - BETHLEHEM, PA. January 4, 2018 OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in po
Read more →OSUROraSure Technologies Announces Management Succession Plan
BETHLEHEM, Pa., Jan. 04, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced a succession plan for its President and Chief Executive Officer (“CEO”) and for its Chief Financ
Read more →OSURFIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this Amendment ) is made as of
FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this Amendment ) is made as of December 20, 2017 by and among the lenders identified on the signature pages hereof (each of such lenders, together with its successors and permitted assigns, is referre
Read more →OSUROraSure Technologies Announces 2018 Annual Meeting Date
BETHLEHEM, Pa., Dec. 08, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2018 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 8, 2018. This will be a completely virtual meeting, c
Read more →OSUROraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell in Honor of World AIDS Day
ADVISORY, Nov. 30, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions, w
Read more →OSUROraSure Technologies Supports World AIDS Day With Innovative Programs to Enable HIV Testing
BETHLEHEM, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced several new HIV testing-related initiatives, in recognition of World AIDS Day. OraSure is worki
Read more →OSUROraSure Technologies to Present at the 2017 Canaccord Genuity Medical Technologies & Diagnostics Forum
BETHLEHEM, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2017 C
Read more →OSUROraSure Technologies to Present at the Stephens 2017 Fall Investment Conference
BETHLEHEM, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephe
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2017 Third Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2017 Third Quarter Financial Results BETHLEHEM, PA November 1, 2017 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic t
Read more →OSUROraSure Announces 2017 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and nine months ended September 30, 2017. Fina
Read more →OSUROraSure Technologies to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
BETHLEHEM, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2017
Read more →OSUROraSure Technologies to Present at CL King’s 15th Annual Best Ideas Conference
BETHLEHEM, Pa., Sept. 06, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at CL King’s
Read more →OSUROraSure Announces 2017 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2017. Financial
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2017 Second Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2017 Second Quarter Financial Results BETHLEHEM, PA August 2, 2017 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity 37th Annual Growth Conference
BETHLEHEM, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canacc
Read more →OSUROraSure Technologies Receives World Health Organization Prequalification of OraQuick HIV Self-Test
BETHLEHEM, Pa., July 21, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that its OraQuick® HIV Self-Test (HIVST) has been Prequalified by the World Health Organization
Read more →OSUROraSure Technologies to Drive Accelerated Adoption of OraQuick HIV Self-Test
BETHLEHEM, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced a new agreement with the Bill & Melinda Gates Foundation that will enable OraSure to offer its O
Read more →OSUROraSure Technologies Appoints Mara G. Aspinall to Board of Directors
BETHLEHEM, Pa., June 22, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of Ms. Mara G. Aspinall as a member of the Company's Board of Directors. Ms. As
Read more →OSURRonald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Technologies
Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com OraSure Technologies Appoints Mara G. Aspinall to Board of Directors BETHLEHEM, PA. June 22
Read more →OSUROraSure Technologies to Present at the Jefferies 2017 Global Healthcare Conference
BETHLEHEM, Pa., May 31, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferi
Read more →OSUROraSure Announces 2017 First Quarter Financial Results
BETHLEHEM, Pa., May 03, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March 31, 2017. Financial Highlig
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2017 First Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2017 First Quarter Financial Results BETHLEHEM, PA May 3, 2017 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today annou
Read more →OSUROraSure Receives Global Fund Classification to Enable HIV Self-Test Procurement
BETHLEHEM, Pa., March 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that its OraQuick® HIV Self-Test has been designated as eligible for procurement by purchasing
Read more →OSUROraSure Technologies to Present at the Raymond James 38th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymon
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Technologies Announces Director Retirement BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Technologies Announces Director Retirement BETHLEHEM, PA February 24, 2017 OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen c
Read more →OSUROraSure Technologies Announces Director Retirement
BETHLEHEM, Pa., Feb. 24, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Roger L. Pringle will be retiring as a member of the Company’s Board of Directors, effectiv
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2016 Fourth Quarter and Full-Year Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2016 Fourth Quarter and Full-Year Financial Results BETHLEHEM, PA February 8, 2017 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection
Read more →OSUROraSure Announces 2016 Fourth Quarter and Full-Year Financial Results
BETHLEHEM, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2016.
Read more →OSURRonald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com ORASURE TECHNOLOGIES
Ronald H. Spair Shauna White Chief Financial Officer Corporate Marketing Manager 610-882-1820 484-353-1575 Investorinfo@orasure.com media@orasure.com www.orasure.com www.orasure.com ORASURE TECHNOLOGIES ANNOUNCES SETTLEMENT OF LITIGATION WITH PA Februar
Read more →OSUROraSure Technologies Announces Settlement of Litigation with Ancestry.comDNA
BETHLEHEM, Pa., Feb. 06, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced the settlement of litigation for patent infringement and breach of contract filed by its subsidiary, DNA Genotek, Inc. (“DNA Genotek”), against Ancestry.comDNA LLC (“Ancestr
Read more →OSUROraSure Technologies Analyst Day
OraSure Technologies Analyst Day November 29, 2016 Nasdaq MarketSite Agenda Welcome and introductions Infectious Disease HCV Country-Wide Elimination Programs HIV Self-Testing R&D: Emerging Diseases -Ebola, Zika Tuberculosis (TB) Molecular Personal Genomics Microbiome R&D: Samp
Read more →OSUROraSure to Implement $18 Million Product Supply Contract From Foreign Government for HCV Elimination Program
BETHLEHEM, Pa., Nov. 29, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it will begin fulfilling a contract to supply a foreign government with $18 million of prod
Read more →OSUROraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Nov. 28, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in point-of-care diagnostic tests and specimen collection devices, will visit the Nasdaq MarketSite in Times Square, to raise awareness about the issues surrounding HIV and AIDS
Read more →OSUROraSure Technologies to Host Analyst Day
BETHLEHEM, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in point-of-care diagnostic tests and specimen collection devices, today announced that it will host an Analyst Day meeting on Tuesday, November 29, 2016 in New York City,
Read more →OSURRonny Lancaster has been appointed to replace Dr. Tang as Chairman of the Compensation Committee. Mr. Lancaster has been a Director since May 2003, has served as Chairman of the Nominating and Corporate Governance Commit
Chief Financial Officer Investorinfo@orasure.com OraSure Technologies Appoints Stephen S. Tang, Ph.D. as Chairman of the Board of Directors BETHLEHEM, PA November 15, 2016 OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen coll
Read more →OSUROraSure Technologies Appoints Stephen S. Tang, Ph.D. as Chairman of the Board of Directors
BETHLEHEM, Pa., Nov. 15, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of Stephen S. Tang, Ph.D., as Chairman of the Company’s Board of Directors (the
Read more →OSUROraSure Technologies to Present at the 10th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
BETHLEHEM, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 10th A
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2016 Third Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2016 Third Quarter Financial Results BETHLEHEM, PA November 2, 2016 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today
Read more →OSUROraSure Announces 2016 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and nine months ended September 30, 2016. Fina
Read more →OSUROraSure Technologies Announces 2017 Annual Meeting Date
BETHLEHEM, Pa., Oct. 14, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2017 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 16, 2017. This will be a completely virtual meeting, c
Read more →OSUROraSure Technologies to Present at the CL King 14th Annual Best Ideas Conference
BETHLEHEM, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the CL Ki
Read more →OSUROraSure Awarded Up to $16.6 Million to Advance Rapid Zika Tests
BETHLEHEM, Pa., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has been awarded a contract for up to $16.6 million in total funding from the U.S. Depar
Read more →OSUROraSure Announces 2016 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2016. Financial
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2016 Second Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2016 Second Quarter Financial Results BETHLEHEM, PA August 3, 2016 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity 36th Annual Growth Conference
BETHLEHEM, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canacc
Read more →OSURORASURE TECHNOLOGIES AND ABBVIE AGREE TO AN EARLY TERMINATION OF HCV CO-PROMOTION AGREEMENT - Investor Conference Call Scheduled Today at 8:30 a.m. Eastern Time - BETHLEHEM, Pa.
ORASURE TECHNOLOGIES AND ABBVIE AGREE TO AN EARLY TERMINATION OF HCV CO-PROMOTION AGREEMENT - Investor Conference Call Scheduled Today at 8:30 a.m. Eastern Time - BETHLEHEM, Pa. July 1, 2016 OraSure Technologies (NASDAQ: OSUR), a market leader in point of care diagnostics, ann
Read more →OSUROraSure Technologies Investor Call Invitation
Investor Conference Call July 1, 2016, 8:30 a.m. ET BETHLEHEM, Pa., June 30, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled an investor conference call and simultaneous webcast for 8:30 a.m. ET (5:30 a.m. PT) on July 1, 2016 to provide an update
Read more →OSUROraSure Technologies to Present at the Jefferies 2016 Healthcare Conference
BETHLEHEM, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferies 2016 Healthcare Conference in New York. The conference will be simultaneou
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2016 First Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2016 First Quarter Financial Results BETHLEHEM, PA May 4, 2016 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today anno
Read more →OSUROraSure Announces 2016 First Quarter Financial Results
BETHLEHEM, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March 31, 2016. Financial Highlig
Read more →OSUROraSure Technologies to Present at the UBS 2016 Global Healthcare Conference
BETHLEHEM, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS 201
Read more →OSUROraSure Technologies Appoints New Chief Science Officer
BETHLEHEM, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that Michael Reed, Ph.D. has been named as the Company’s Senior Vice President of Research and Development and Chief Science Officer. He will begin working at the Company o
Read more →OSUROraSure Technologies Appoints Eamonn P. Hobbs to its Board of Directors
BETHLEHEM, Pa., March 23, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), today announced the appointment of Mr. Eamonn P. Hobbs as a member of the Company's Board of Directors. Mr. Hobbs will serve as a Class I Director with an initial term expiring at the Com
Read more →OSURInvestor Contact: Ronald H. Spair Chief Financial Officer (610) 882-1820 investorinfo@orasure.com OraSure Technologies Appoints Eamonn P. Hobbs to its Board of Directors BETHLEHEM, PA .
Chief Financial Officer investorinfo@orasure.com Technologies Appoints Eamonn P. Hobbs to its Board of Directors BETHLEHEM, PA. March 23, 2016 OraSure Technologies, Inc. (NASDAQ: OSUR), today announced the appointment of Mr. Eamonn P. Hobbs as a member of the Company s Board
Read more →OSUROraSure Technologies to Present at the Raymond James 37th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 26, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 37th Annual Institutional Investors Conference in Orlando, Florida. T
Read more →OSUROraSure Announces Record Revenues for Full-Year and Fourth Quarter 2015
BETHLEHEM, Pa., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the full-year and fourth quarter ended December 31, 2015.
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Record Revenues for Full-Year and Fourth Quarter 2015 BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces Record Revenues for Full-Year and Fourth Quarter 2015 BETHLEHEM, PA February 3, 2016 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collecti
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
BETHLEHEM, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canacc
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2015 Third Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2015 Third Quarter Financial Results BETHLEHEM, PA November 4, 2015 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today
Read more →OSUROraSure Announces 2015 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and nine months ended September 30, 2015. Fina
Read more →OSUROraSure Technologies Provides Update on OraQuick Ebola Rapid Antigen Test Business
BETHLEHEM, Pa., Sept. 29, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has made significant progress regarding the commercialization of its OraQuick Ebola Rap
Read more →OSUROraSure Technologies Announces 2016 Annual Meeting Date
BETHLEHEM, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2016 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2016. Further details regarding the meeting will be provided at a later date. About
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2015 Second Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2015 Second Quarter Financial Results BETHLEHEM, PA August 5, 2015 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today a
Read more →OSUROraSure Announces 2015 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2015. Financial H
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity 35th Annual Growth Conference
BETHLEHEM, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canacco
Read more →OSUROrasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
BETHLEHEM, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA)
Read more →OSUROraSure Supports Rapid HIV Testing Initiatives in Recognition of National HIV Testing Day
BETHLEHEM, Pa., June 26, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced its support of various rapid HIV testing initiatives and events taking place this week in recogn
Read more →OSUROraSure Technologies to Present at the 2015 JMP Securities Life Sciences Conference
BETHLEHEM, Pa., June 16, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2015 JMP Securities Life Sciences Conference in New York. The conference will be si
Read more →OSUROraSure Awarded $10.4 Million HHS Contract to Advance Rapid Ebola Test Clinical Development
BETHLEHEM, Pa., June 12, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has been awarded a contract for up to $10.4 million in total funding from the U.S. Depar
Read more →OSUROrasure Technologies to Present at the Jefferies 2015 Global Healthcare Conference
BETHLEHEM, Pa., May 22, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferies 2015 Global Healthcare Conference in New York. The conference will be simu
Read more →OSUROraSure Technologies Supports Rapid HCV Testing Initiatives Across the U.S. in Recognition of National Hepatitis Testing Day
BETHLEHEM, Pa., May 19, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced its support of numerous rapid hepatitis C (HCV) testing events for National Hepatitis Testing Day
Read more →OSUROraSure Technologies to Present at the UBS Global Healthcare Conference 2015
BETHLEHEM, Pa., May 11, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS Global Healthcare Conference 2015 in New York. The conference will be simultaneo
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2015 First Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2015 First Quarter Financial Results BETHLEHEM, PA May 6, 2015 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests
Read more →OSUROraSure Announces 2015 First Quarter Financial Results
BETHLEHEM, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March 31, 2015. Financial Highligh
Read more →OSUROraSure Technologies to Webcast Annual Meeting of Stockholders
BETHLEHEM, Pa., May 4, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), announced that it will webcast its 2015 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Monday, May 11, 2015. In order to access the webcast,
Read more →OSURAMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This Amendment No. 3 to Employment Agreement entered into as of
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This Amendment No. 3 to Employment Agreement entered into as of March 27, 2015 (this Amendment ), between Douglas A. Michels ( Employee ) and OraSure Technologies, Inc., a Delaware corporation (the Company ). WHEREAS, the parties have p
Read more →OSUROraSure Technologies to Present at the Cowen & Company 35th Annual Health Care Conference
BETHLEHEM, Pa., Feb. 24, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Company 35th Annual Health Care Conference in Boston, Massachusetts. The co
Read more →OSUROraSure Technologies to Present at the Raymond James 36th Annual Institutional Investor Conference
BETHLEHEM, Pa., Feb. 23, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 36th Annual Institutional Investor Conference in Orlando, Florida. Th
Read more →OSUROraSure Announces Full-Year and Fourth Quarter 2014 Financial Results
BETHLEHEM, Pa., Feb. 4, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter ended December 31, 2014. Financial Highlights The Compan
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Full-Year and Fourth Quarter 2014 Financial Results 2014 Revenues Exceed $100 million BETHL
Chief Financial Officer Investorinfo@orasure.com OraSure Announces Full-Year and Fourth Quarter 2014 Financial Results 2014 Revenues Exceed $100 million BETHLEHEM, PA February 4, 2015 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid d
Read more →OSUROraSure Technologies Announces 2015 Annual Meeting Date
BETHLEHEM, Pa., Dec. 2, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2015 Annual Meeting of Stockholders is scheduled to be held on Monday, May 11, 2015. Further details regarding the meeting will be provided at a later date. About O
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity Medical Technology & Diagnostics Conference
BETHLEHEM, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity Medical Technology & Diagnostic Conference in New York City, New
Read more →OSUROraSure Technologies to Present at the Stephens 2014 Fall Investment Conference
BETHLEHEM, Pa., Nov. 7, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens 2014 Fall Investment Conference in New York City, New York. The conference
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2014 Third Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2014 Third Quarter Financial Results BETHLEHEM, PA November 5, 2014 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated finan
Read more →OSUROraSure Announces 2014 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the three and nine months ended September 30, 2014. Financial Highlights Consolidated net
Read more →OSUROraSure Announces 2014 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 6, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the three and six months ended June 30, 2014. Financial Highlights Consolidated net reven
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2014 Second Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2014 Second Quarter Financial Results BETHLEHEM, PA August 6, 2014 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financ
Read more →OSUROraSure Technologies to Present at the Canaccord Genuity 34th Annual Growth Conference
BETHLEHEM, Pa., Aug. 6, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 34th Annual Growth Conference in Boston, Massachusetts. The confer
Read more →OSURRonald H. Spair Media Contact: Chief Financial Officer Jennifer Moritz 610-882-1820 Zer0 to 5ive for OraSure Technologies Investorinfo@orasure.com 917-748-4006 www.orasure.com jmoritz@0to5.com ORASURE PROVIDES UPDATE ON
Ronald H. Spair Media Contact: Chief Financial Officer Jennifer Moritz 610-882-1820 Zer0 to 5ive for OraSure Technologies Investorinfo@orasure.com 917-748-4006 www.orasure.com jmoritz@0to5.com ORASURE PROVIDES UPDATE ON SUBSTANCE ABUSE TESTING BUSINESS Company Now Projects
Read more →OSUROraSure Provides Update on Substance Abuse Testing Business
BETHLEHEM, Pa., June 25, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies (Nasdaq:OSUR), a market leader in point of care diagnostics, announced today continued progress under its agreement with Thermo Fisher Scientific (Thermo Fisher) to develop and supply homogenous fully-automate
Read more →OSUROraSure Technologies to Present at the JMP Securities Healthcare Conference
BETHLEHEM, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the JMP Securities Healthcare Conference in New York, New York. The conference will be
Read more →OSURRonald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 Investorinfo@orasure.com jmoritz@0to5.com www.orasure.com ORASURE TE
Company Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 Investorinfo@orasure.com jmoritz@0to5.com www.orasure.com ORASURE TECHNOLOGIES ANNOUNCES NEW CO-PROMOTION AGREEMENT FOR
Read more →OSUROraSure Technologies Announces New Co-Promotion Agreement for OraQuick(R) HCV Rapid Antibody Test
BETHLEHEM, Pa., June 11, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies (Nasdaq:OSUR), a market leader in point of care diagnostics, announced today that it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie under which AbbVie and OraSure will co-pro
Read more →OSUROraSure Technologies to Present at Jefferies 2014 Global Healthcare Conference
BETHLEHEM, Pa., May 28, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferies 2014 Global Healthcare Conference in New York City. The conference will be
Read more →OSUROraSure Technologies Announces Rapid HCV Testing Initiatives Across the U.S. in Support of National Hepatitis Testing Day
BETHLEHEM, Pa., May 19, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for National Hepatitis Testing Day, taking place on May 19, 2014. These testing initiatives, happening acr
Read more →OSUROraSure Technologies, Inc. (NASDAQ: OSUR) to Ring The NASDAQ Stock Market Closing Bell in Recognition of National Hepatitis Testing Day on May 19th
ADVISORY, May 16, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions, in
Read more →OSUROraSure Announces 2014 First Quarter Financial Results
BETHLEHEM, Pa., May 7, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2014. Financial Highlights Consolidated net revenues for the first qu
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2014 First Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2014 First Quarter Financial Results BETHLEHEM, PA May 7, 2014 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial
Read more →OSUROraSure Technologies' Debra Fraser-Howze Receives 2014 "Top Blacks in Healthcare" Award
BETHLEHEM, Pa., April 4, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) is proud to announce that Debra Fraser-Howze, the Company's Senior Vice President of Government and External Affairs, received a 2014 "Top Blacks in Healthcare" Award from BlackDoctor.org i
Read more →OSUROraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
BETHLEHEM, Pa., Feb. 26, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34th Annual Health Care Conference in Boston, Massachusetts. The confer
Read more →OSUROraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 24, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35th Annual Institutional Investors Conference in Orlando, Florida. T
Read more →OSUROraSure Technologies to Present at the 2014 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 20, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2014 Citi Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Technologies to Present at the Leerink Swan Global Healthcare Conference
BETHLEHEM, Pa., Feb. 6, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald Spair, Chief Operating Officer & Chief Financial Officer, will speak to the investment community at the Leerink Swan Global Healthcare Conference in New York City
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Record Full-Year and Quarterly Revenues BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces Record Full-Year and Quarterly Revenues BETHLEHEM, PA February 5, 2014 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated fi
Read more →OSUROraSure Announces Record Full-Year and Quarterly Revenues
BETHLEHEM, Pa., Feb. 5, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2013. Financial Highlights The Company reported recor
Read more →OSUROraSure Technologies Announces 2014 Annual Meeting Date
BETHLEHEM, Pa., Jan. 28, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2014 Annual Meeting of Stockholders is scheduled to be held on Thursday, May 22, 2014. Further details regarding the meeting will be provided at a later date. Abou
Read more →OSUROraSure Technologies Addresses FDA Warning Letter Received by Its Subsidiary DNA Genotek
BETHLEHEM, Pa., Jan. 7, 2014 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced that its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) which the FDA posted today on its website.
Read more →OSURInvestor Contact: Media Contact: Ron Spair Jennifer Moritz OraSure Technologies Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Addresses FDA
Investor Contact: Media Contact: Ron Spair Jennifer Moritz OraSure Technologies Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Addresses FDA Warning Letter Received by its Subsidiary DNA Genotek
Read more →OSUROraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance
BETHLEHEM, Pa., Nov. 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it is reaffirming its fourth quarter 2013 financial guidance, which the Company last updated in a press release it issued on November 21, 2013. This reaffirmation is b
Read more →OSURInvestor Contact: Ron Spair OraSure Technologies 610-882-1820 investorinfo@orasure.com OraSure Technologies Reaffirms 4 th Quarter 2013 Financial Guidance BETHLEHEM, Pa.
OraSure Technologies investorinfo@orasure.com OraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance BETHLEHEM, Pa. November 25, 2013 OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it is reaffirming its fourth quarter 2013 financial guidance, which
Read more →OSUROraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration With Roche Diagnostics
BETHLEHEM, Pa., Nov. 21, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its assay collaboration agreement with Roche Diagnostics has been terminated. As part of the termination, Roche will continue to supply certain of the assays developed
Read more →OSURInvestor Contact: Media Contact: Ron Spair Jennifer Moritz OraSure Technologies Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Terminates Or
Investor Contact: Media Contact: Ron Spair Jennifer Moritz OraSure Technologies Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration with Roch
Read more →OSUROraSure Technologies Announces New Agreement With Thermo Fisher Scientific for Development and Distribution of Fully Automated Oral Fluid Drugs of Abuse Assays
BETHLEHEM, Pa., Nov. 21, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has reached an agreement with Thermo Fisher Scientific (Thermo Fisher), to develop and supply up to 12 homogenous fully automated oral fluid drugs of abuse assays to
Read more →OSUROraSure Technologies to Present at Canaccord|Genuity's Medical Technology & Diagnostics Forum
BETHLEHEM, Pa., Nov. 7, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at Canaccord|Genuity's Medical Technology & Diagnostics Forum in New York City. The conference will be
Read more →OSUROraSure Announces 2013 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter and nine months ended September 30, 2013. Financial Highlights Consolid
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2013 Third Quarter Financial Results Quarterly Revenues Reach Record High BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2013 Third Quarter Financial Results Quarterly Revenues Reach Record High BETHLEHEM, PA November 6, 2013 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics,
Read more →OSUROraSure Technologies Commends New York State Hepatitis C Testing Law
BETHLEHEM, Pa., Oct. 23, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) applauds New York State's new hepatitis C (HCV) testing law, which requires providers in all clinical settings in the state of New York (except emergency rooms) to offer a one-time HCV test
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2013 Second Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2013 Second Quarter Financial Results BETHLEHEM, PA August 7, 2013 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financ
Read more →OSUROraSure Announces 2013 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 7, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2013. Financial Highlights Consolidated
Read more →OSUROraSure Technologies to Present at Canaccord|Genuity's 33rd Annual Growth Conference
BETHLEHEM, Pa., Aug. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 33rd Annual Growth Conference in Boston, MA. The conference will be
Read more →OSUROraSure Technologies to Present at the Eighth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., July 8, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Eighth Annual JMP Securities Healthcare Conference in New York City. The conference
Read more →OSUROraSure Technologies Teams With The Reed For Hope Foundation, Singer/Songwriter/Actress Keri Hilson and Dr. Rachael Ross to Encourage America to Get Tested for HIV
BETHLEHEM, Pa., June 26, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it has teamed up with The Reed For Hope Foundation and their new ambassador, award-winning singer/songwriter/actress Keri Hilson, and medical doctor and sexologist Dr.
Read more →OSUROraSure Technologies Praises New Hepatitis C Testing Recommendations by U.S. Preventive Services Task Force
BETHLEHEM, Pa., June 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today its support for the new recommendations issued today by the U.S. Preventive Services Task Force (USPSTF), giving both hepatitis C (HCV) screening for at-risk individuals and
Read more →OSUROraSure Technologies to Present at Jefferies 2013 Global Healthcare Conference
BETHLEHEM, Pa., May 28, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2013 Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Technologies, Walgreens and Chronic Liver Disease Foundation to Launch Rapid Hepatitis C Testing Initiative in Support of National Hepatitis Testing Day
BETHLEHEM, Pa., May 13, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), Walgreens (NYSE:WAG), and the Chronic Liver Disease Foundation announced today that they have joined with local health organizations to offer hepatitis C (HCV) testing with the OraQuick HCV
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2013 First Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2013 First Quarter Financial Results BETHLEHEM, PA May 8, 2013 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics,
Read more →OSUROraSure Announces 2013 First Quarter Financial Results
BETHLEHEM, Pa., May 8, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2013. Quarterly Highlights Consolidated net revenues were $21.2 milli
Read more →OSUROraSure Technologies to Participate at Needham's Twelfth Annual Healthcare Conference
BETHLEHEM, Pa., April 29, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at Needham's Twelfth Annual Healthcare Conference in New York City at
Read more →OSUROraSure Technologies to Present at the Cowen & Company 33rd Annual Health Care Conference
BETHLEHEM, Pa., Feb. 26, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 33rd Annual Health Care Conference in Boston, Massachusetts. The confer
Read more →OSUROraSure Technologies to Present at the Raymond James 34th Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 22, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 34th Annual Institutional Investors Conference in Orlando, Florida. T
Read more →OSUROraSure Technologies to Present at the 2013 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 19, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2013 Citi Global Healthcare Conference in New York City. The conference will be sim
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Full-Year and Fourth Quarter 2012 Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces Full-Year and Fourth Quarter 2012 Financial Results BETHLEHEM, PA February 6, 2013 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its cons
Read more →OSUROraSure Announces Full-Year and Fourth Quarter 2012 Financial Results
BETHLEHEM, Pa., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2012. Quarterly Highlights Consolidated net revenues
Read more →OSURJennifer Moritz Zer0 to 5ive for OraSure Technologies 917-748-4006 jmoritz@0to5.com OraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business Company to Launch N
Zer0 to 5ive for OraSure Technologies OraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business Company to Launch National Television Advertising Campaign for OraQuick In-Home HIV Test on World AIDS Day, December 1st November 28, 2
Read more →OSUROraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business
BETHLEHEM, Pa., Nov. 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has appointed Kathleen G. Weber as the Company's Senior Vice President and General Manager, Consumer Products. Her appo
Read more →OSUROraSure Technologies Praises New Routine HIV Screening Recommendations by U.S. Preventive Services Task Force
BETHLEHEM, Pa., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today its support for the draft recommendations issued yesterday by the U.S. Preventive Services Task Force (USPSTF), calling for routine HIV testing for all people ages 15 to 65.
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2012 Third Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2012 Third Quarter Financial Results BETHLEHEM, PA November 7, 2012 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated finan
Read more →OSUROraSure Announces 2012 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter and nine months ended September 30, 2012. Quarterly Highlights Consolid
Read more →OSUROraSure Technologies to Present at the Stephens, Inc. Fall Investment Conference
BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens Fall Investment Conference in New York City. The conference will be simulta
Read more →OSUROraSure Technologies Joins With Actress/Model Dayana Mendoza and the Latino Commission on AIDS to Promote the OraQuick(R) In-Home HIV Test for National Latino AIDS Awareness Day
OraQuick In-Home HIV Test Now Available in Retail Stores Nationwide Press Conference at New York City Hall Monday, October 15 @ 10:00 AM BETHLEHEM, Pa., Oct. 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will join with actress/mod
Read more →OSUROraSure Technologies to Participate at the UBS Global Life Sciences Conference
BETHLEHEM, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conf
Read more →OSUROraSure Technologies to Present at ThinkEquity's Ninth Annual Growth Conference
BETHLEHEM, Pa., Sept. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's Ninth Annual Growth Conference in New York City. The conference will be s
Read more →OSUROraSure Technologies Announces 2013 Annual Meeting Date
BETHLEHEM, Pa., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2013 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 14, 2013. Further details regarding the meeting will be provided at a later date. About
Read more →OSUROraSure Technologies Applauds New CDC Recommendations That All Baby Boomers be Tested for Hepatitis C
BETHLEHEM, Pa., Aug. 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its enthusiastic support for the expanded hepatitis C testing recommendations issued by the Centers for Disease Control and Pre
Read more →OSUROraSure Technologies to Present at Canaccord|Genuity's 32nd Annual Growth Conference
BETHLEHEM, Pa., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 32nd Annual Growth Conference in Boston, MA. The conference will be
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2012 Second Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2012 Second Quarter Financial Results BETHLEHEM, PA August 7, 2012 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnost
Read more →OSUROraSure Announces 2012 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2012. Financial Highlights Consolidated
Read more →OSUROraSure Technologies Supports Rapid HCV Testing Initiatives for World Hepatitis Day
BETHLEHEM, Pa., July 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for World Hepatitis Day, taking place on July 28, 2012. The
Read more →OSUROraSure Technologies, Inc. [OSUR] to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, July 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. [OSUR], leaders in the development, manufacture and distribution of technologies used to detect or diagnose critical medical conditions, including HCV and HIV, will visit the NASDAQ MarketSite in Times Square
Read more →OSUROraSure Technologies, Inc. Announces Closing of Underwritten Offering of Common Stock
BETHLEHEM, Pa., July 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the closing of its previously announced public offering of common stock. As a result, the Company issued a total of 6,100,000 shares in the offering at a price of $12.30 per
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 investorinfo@orasure.com OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock BETHLEHEM, Pa.
Chief Financial Officer investorinfo@orasure.com OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock BETHLEHEM, Pa., July 10, 2012 OraSure Technologies, Inc. (NASDAQ: OSUR) today announced the pricing of an underwritten offering of 6,100,000 shares of its c
Read more →OSUROraSure Technologies to Present at the Seventh Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., July 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Seventh Annual JMP Securities Healthcare Conference in New York City. The conference
Read more →OSUROraSure Technologies, Inc. Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels Please see Important Information at the conclusion of the following prepared remarks. Thanks Judy and good morning everyone. The purpose of today s call is to provide addition
Read more →OSURInvestor Contact: Ronald H. Spair Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Ashley Buford GolinHarris for OraSure Technologies 917-653-5694 abuford@golinharris.com OraSure Receives FDA
OraSure Receives FDA Approval of OraQuick In-Home HIV Test First and Only Rapid HIV Test For Over the Counter Use To be Available in October for Purchase Online and at Retail Stores Nationwide BETHLEHEM, Pa., July 3, 2012 OraSure Technologies, Inc. (NASDAQ: OSUR) today announce
Read more →OSUROraSure Receives FDA Approval of OraQuick(R) In-Home HIV Test
BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's OraQuick In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market - ma
Read more →OSUROraSure Technologies Conference Call Invitation
BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will hold a conference call covering the recent U.S. Food and Drug Administration approval of the OraQuick In-Home HIV Test and the Company's plans to commercialize t
Read more →OSUROraSure Supports Rapid HIV Testing Initiatives in Recognition of 18th Annual National HIV Testing Day
BETHLEHEM, Pa., June 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of various rapid HIV testing initiatives in recognition of National HIV Testing Day, held each year on June 27th. N
Read more →OSUROraSure Technologies, Inc. [OSUR], President & CEO, to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, June 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. [OSUR], leaders in the development, manufacture and distribution of technologies used to detect or diagnose critical medical conditions, including HIV and HCV, will visit the NASDAQ MarketSite in Times Square
Read more →OSUROraSure Technologies to Present at Jefferies 2012 Global Healthcare Conference
BETHLEHEM, Pa., May 29, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2012 Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Technologies Announces Rapid HCV Testing Initiatives for First National Hepatitis Testing Day
BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for the first National Hepatitis Testing Day, taking place on May 19, 2012. These testing initiatives, hap
Read more →OSUROraSure Technologies Applauds CDC Proposed Draft Guidelines for Testing of Baby Boomers for Hepatitis C
BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in strong support of the Center for Disease Control and Prevention (CDC) draft guidelines proposing that all U.S. baby boomers get a one-time test for the hepatitis
Read more →OSURInvestor Contact: Ronald H. Spair Chief Financial Officer 610-882-1820 investorinfo@orasure.com Media Contact: Ashley Buford GolinHarris for OraSure Technologies 917-653-5694 abuford@golinharris.com OraQuick In-Home HIV
OraQuick In-Home HIV Test Receives Unanimous Positive Recommendation from FDA Advisory Committee BETHLEHEM, PA, May 15, 2012 OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) prov
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2012 First Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2012 First Quarter Financial Results BETHLEHEM, PA May 2, 2012 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial
Read more →OSUROraSure Announces 2012 First Quarter Financial Results
BETHLEHEM, Pa., May 2, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2012. Financial Highlights Consolidated revenues were $20.9 million f
Read more →OSUROraSure Technologies to Present at Deutsche Bank's 37th Annual Health Care Conference
BETHLEHEM, Pa., April 30, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 37th Annual Health Care Conference in Boston, Massachusetts. The confe
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Ashley Buford Chief Financial Officer GolinHarris for OraSure Technologies 610-882-1820 917-653-5694 investorinfo@orasure.com abuford@golinharris.com FDA Sets Date for Adv
Investor Contact: Media Contact: Ronald H. Spair Ashley Buford Chief Financial Officer GolinHarris for OraSure Technologies 610-882-1820 917-653-5694 investorinfo@orasure.com abuford@golinharris.com FDA Sets Date for Advisory Committee Review of OraSure Over-the-Counter Ra
Read more →OSUROraSure Technologies to Present at the 11th Annual Needham Healthcare Conference
BETHLEHEM, Pa., March 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 11th Annual Needham Healthcare Conference in New York City. The conference will be s
Read more →OSUROraSure Technologies to Present at the Cowen & Co. 32nd Annual Health Care Conference
BETHLEHEM, Pa., Feb. 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 32nd Annual Health Care Conference in Boston, Massachusetts. The confer
Read more →OSUROraSure Technologies to Present at the 2012 RBC Capital Markets' Healthcare Conference
BETHLEHEM, Pa., Feb. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the 2012 RBC Capital Markets Healthcare Conference in New York City. The conference will be simult
Read more →OSUROraSure Technologies to Present at the 2012 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2012 Citi Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Announces Fourth Quarter and Full-Year 2011 Financial Results
BETHLEHEM, Pa., Feb. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the fourth quarter and full year of 2011. Financial Highlights Consolidated revenues were
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Fourth Quarter and Full-Year 2011 Financial Results Company Reports Record Quarterly Revenu
Chief Financial Officer Investorinfo@orasure.com OraSure Announces Fourth Quarter and Full-Year 2011 Financial Results Company Reports Record Quarterly Revenues BETHLEHEM, PA February 8, 2012 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral
Read more →OSUROraSure Technologies to Participate at the Fourteenth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan. 6, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fourteenth Annual Needham Growth Conference in New York at appro
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Ashley Buford Chief Financial Officer GolinHarris for OraSure Technologies 610-882-1820 917-653-5694 investorinfo@orasure.com abuford@golinharris.com OraSure Makes Final F
Investor Contact: Media Contact: Ronald H. Spair Ashley Buford Chief Financial Officer GolinHarris for OraSure Technologies 610-882-1820 917-653-5694 investorinfo@orasure.com abuford@golinharris.com OraSure Makes Final FDA Submission for Approval of Over-the-Counter Rapid
Read more →OSUROraSure Makes Final FDA Submission for Approval of Over-the-Counter Rapid HIV Test
BETHLEHEM, Pa., Jan. 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in rapid point-of-care infectious disease diagnostics and biological sample collection, stabilization and preparation products, announced today that it has submitted the fin
Read more →OSURThe CORPORATE plan for Retirement SM EXECUTIVE P LAN BASIC PLAN DOCUMENT IMPORTANT NOTE This document has not been approved by the Department of Labor, the Internal Revenue Service or any other governmental entity. The E
The CORPORATEplan for RetirementSM This document has not been approved by the Department of Labor, the Internal Revenue Service or any other governmental entity. The Employer must determine whether the plan is subject to the Federal securities laws and the securities laws of th
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Rece
Investor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Receives CLIA Waiver for OraQuick HCV Rapid Test BETHLEHE
Read more →OSUROraSure Technologies Receives CLIA Waiver for OraQuick(R) HCV Rapid Test
BETHLEHEM, Pa., Nov. 29, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that the U.S. Food and Drug Administration ("FDA") has granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick HCV Rapid Anti
Read more →OSUROraSure Technologies Appoints Veteran Consumer Products Executive to Its Board of Directors
BETHLEHEM, Pa., Nov. 10, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Gerald M. Ostrov as a member of the Company's Board of Directors. Mr. Ostrov will serve as a Class I Director with an initial term expiring in 2013. "We
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Appo
Investor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Appoints Veteran Consumer Products Executive to its Board
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2011 Third Quarter Consolidated Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2011 Third Quarter Consolidated Financial Results BETHLEHEM, PA November 2, 2011 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced its conso
Read more →OSUROraSure Announces 2011 Third Quarter Consolidated Financial Results
BETHLEHEM, Pa., Nov. 2, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter of 2011. Quarterly Highlights The Company completed the acquisition of
Read more →OSUROraSure Applauds American Academy of Pediatrics Updated Recommendations for Routine HIV Screening for Adolescents
BETHLEHEM, Pa., Nov. 1, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in support of updated recommendations issued by the American Academy of Pediatrics ("AAP") on HIV screening for adolescents. These recommendations, which advocate re
Read more →OSUROraSure Technologies to Participate at the Sixth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., Sept. 21, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Sixth Annual JMP Securities Healthcare Conference in New York
Read more →OSUROraSure Technologies Announces 2012 Annual Meeting Date
BETHLEHEM, Pa., Sept. 6, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2012 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 15, 2012. Further details regarding the meeting will be provided at a later date. About
Read more →OSUROraSure Technologies to Participate at the William Blair 2011 Life Sciences Conference
BETHLEHEM, Pa., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Dr. Stephen R. Lee, Chief Science Officer & EVP R&D, will participate on a panel at the William Blair 2011 Life Sciences Conference in New York City. The panel discussi
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Anno
Investor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies Announces Closing of DNA Genotek Acquisition BETHLEHEM, P
Read more →OSUROraSure Technologies Announces Closing of DNA Genotek Acquisition
BETHLEHEM, Pa., Aug. 18, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has completed its previously-announced acquisition of DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products fo
Read more →OSUROraSure Closes Enrollment in Final Clinical Study for Rapid HIV Over-the-Counter Test
BETHLEHEM, Pa., Aug. 9, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has closed enrollment for its multi-site clinical study of the Company's OraQuick Rapid HIV-1/2 test for sale in the U.S
Read more →OSUROraSure Announces 2011 Second Quarter Financial Results
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2011 Second Quarter Financial Results BETHLEHEM, PA August 3, 2011 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $19.1
Read more →OSUROraSure Technologies, Inc. 2011 Second Quarter Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Please see Important Information at the conclusion of the following prepared remarks. Introduction Doug Michels Thanks Judy, and good afternoon everyone. As indicated in o
Read more →OSUROraSure Technologies to Present at Canaccord Genuity's 31st Annual Growth Conference
BETHLEHEM, Pa., Aug. 3, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 31st Annual Growth Conference in Boston, MA. The conference will be
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies to A
Investor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com OraSure Technologies to Acquire DNA Genotek Inc. Acquisition Provides Entry in
Read more →OSUROraSure Technologies to Acquire DNA Genotek Inc.; Acquisition Provides Entry Into Rapidly Growing Molecular Diagnostics Market and Strengthens Company's Leadership in Oral Fluid Diagnostics
BETHLEHEM, Pa., July 25, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it will acquire privately-held DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic app
Read more →OSUROraSure Technologies Supports 17th Annual National HIV Testing Day
BETHLEHEM, Pa., June 27, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid HIV testing initiatives in recognition of National HIV Testing Day, held annually on June 27th. N
Read more →OSUROraSure Technologies, Inc. (OSUR), President and CEO, to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, June 24, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (OSUR), developer, manufacturer and marketer of the nation's only FDA-approved rapid HIV test that can be used with oral fluid and blood, will visit the NASDAQ MarketSite in New York City's Times Square. In
Read more →OSUROraSure Technologies to Present at Jefferies 2011 Global Healthcare Conference
BETHLEHEM, Pa., June 2, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2011 Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Technologies to Present At ThinkEquity's 2nd Annual Healthcare Conference
BETHLEHEM, Pa., May 19, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's 2nd Annual Healthcare Conference in New York City. The conference will be
Read more →OSUROraSure Technologies, Inc. 2011 First Quarter Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Ronald Please see Important Information at the conclusion of the following prepared remarks. Introduction Doug Michels Thanks Judy, and good afternoon everyone. 2011 has g
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2011 First Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2011 First Quarter Financial Results BETHLEHEM, PA May 4, 2011 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $17.4 mil
Read more →OSUROraSure Announces 2011 First Quarter Financial Results
BETHLEHEM, Pa., May 4, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $17.4 million for the three months ended March 31, 2011, compared to $17.9 million recorded for the three months
Read more →OSUROraSure Technologies to Present at Deutsche Bank's 36th Annual Health Care Conference
BETHLEHEM, Pa., April 25, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 36th Annual Health Care Conference in Boston, Massachusetts. The confe
Read more →OSURInvestor Contact: Ronald H. Spair Chief Financial Officer 610-882-1820 investorinfo@orasure.com OraSure Technologies Appoints Stephen S. Tang, Ph.D. to its Board of Directors BETHLEHEM, Pa.
Chief Financial Officer investorinfo@orasure.com OraSure Technologies Appoints Stephen S. Tang, Ph.D. to its Board of Directors BETHLEHEM, Pa. April 7, 2011 OraSure Technologies, Inc. (NASDAQ: OSUR), today announced the appointment of Stephen S. Tang, Ph.D. as a member of the
Read more →OSUROraSure Technologies Appoints Stephen S. Tang, Ph.D. to Its Board of Directors
BETHLEHEM, Pa., April 7, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), today announced the appointment of Stephen S. Tang, Ph.D. as a member of the Company's Board of Directors. Dr. Tang will serve as a Class I Director with an initial term expiring at the Co
Read more →OSUROraSure Technologies to Present at the 10th Annual Needham Healthcare Conference
BETHLEHEM, Pa., March 28, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 10th Annual Needham Healthcare Conference in New York City. The conference will be s
Read more →OSUROraSure Technologies Submits CLIA Waiver Application for OraQuick(R) HCV Rapid Test
BETHLEHEM, Pa., March 23, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has submitted to the U.S. Food and Drug Administration ("FDA") an application for a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for
Read more →OSUROraSure Technologies to Present at the Roth 23rd Annual OC Growth Stock Conference
BETHLEHEM, Pa., March 4, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the Roth 23rd Annual OC Growth Stock Conference in Dana Point, California. The conference will be
Read more →OSUROraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays
BETHLEHEM, Pa., March 3, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Food and Drug Administration ("FDA") has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays
Read more →OSUROraSure Technologies to Present at the Cowen & Co. Health Care Conference
BETHLEHEM, Pa., March 1, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be
Read more →OSUROraSure Technologies to Present at the 2011 RBC Capital Markets Healthcare Conference
BETHLEHEM, Pa., Feb. 28, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 RBC Capital Markets Healthcare Conference in New York City. The conference wil
Read more →OSUROraSure Technologies to Present at the 2011 Citi Global Healthcare Conference
BETHLEHEM, Pa., Feb. 24, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 Citi Global Healthcare Conference in New York City. The conference will be sim
Read more →OSUROraSure Technologies Receives FDA Approval for Its OraQuick(R) HCV Rapid Test Using Fingerstick Whole Blood
BETHLEHEM, Pa., Feb. 22, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies with a fingerstick whole
Read more →OSUROraSure Technologies, Inc. 2010 Fourth Quarter and Full Year Analyst/Investor Conference Call
OraSure Technologies, Inc. 2010 Fourth Quarter and Full Year Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Please see Important Information at the conclusion of the following prepared remarks. Introduction Doug Michels Thanks Judy, and good aft
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Fourth Quarter and Full Year 2010 Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Fourth Quarter and Full Year 2010 Financial Results PA February 9, 2011 (GlobeNewswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagn
Read more →OSUROraSure Announces Fourth Quarter and Full Year 2010 Financial Results
BETHLEHEM, Pa., Feb. 9, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to reven
Read more →OSUROraSure Technologies to Launch OraSure QuickFlu(TM) Rapid Flu A+B Test
BETHLEHEM, Pa., Jan. 11, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration ("FDA") approved in vitro rapid qualitative test for the detection o
Read more →OSUROraSure Technologies to Participate at the Thirteenth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan. 7, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Thirteenth Annual Needham Growth Conference in New York at appro
Read more →OSURInvestor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com Accomplished Sales and Ma
Investor Contact: Media Contact: Ronald H. Spair Jennifer Moritz Chief Financial Officer Zer0 to 5ive for OraSure Technologies 610-882-1820 917-748-4006 investorinfo@orasure.com jmoritz@0to5.com Accomplished Sales and Marketing Executive Joins OraSure Technologies BETHLEH
Read more →OSUROraSure Initiates Enrollment in Final Clinical Study for OraQuick(R) Rapid HIV Over-the-Counter Test
BETHLEHEM, Pa., Dec. 13, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("
Read more →OSUROraSure Technologies Announces 2011 Annual Meeting Date
BETHLEHEM, Pa., Dec. 2, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2011 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2011. A location for the meeting will be announced at a later date. About OraSure Te
Read more →OSUROraSure Technologies Supports Rapid HIV Testing Initiatives for World AIDS Day
BETHLEHEM, Pa., Dec. 1, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 rapid HIV testing initiatives taking place in more than 25 states in the U.S. and numerous countrie
Read more →OSUROraSure Technologies, Inc. (OSUR) President and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, Nov. 30, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (OSUR), the market leader in oral fluid diagnostics, will visit the NASDAQ MarketSite in New York City's Times Square to raise awareness for World AIDS Day. In honor of World AIDS Day, Community Healthcare N
Read more →OSUROraSure Technologies Receives FDA Approval to Conduct Final Phase of Clinical Studies for OraQuick(R) Over-the-Counter HIV Test
BETHLEHEM, Pa., Nov. 22, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that the U.S. Food and Drug Administration ("FDA") has granted an investigational device exemption (IDE) for the Company to con
Read more →OSUROraSure Technologies to Participate at the Stephens Fall Investment Conference
BETHLEHEM, Pa., Nov. 10, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Stephens Fall Investment Conference in New York City at approxi
Read more →OSUROraSure Technologies, Inc. 2010 Third Quarter Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Ronald H. Spair Important Information at the conclusion of the following prepared remarks. Thanks Judy, and good afternoon everyone. I am pleased to announce that we delive
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2010 Third Quarter Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2010 Third Quarter Financial Results BETHLEHEM, PA November 9, 2010 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.0 mill
Read more →OSUROraSure Announces 2010 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 9, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.0 million for the three months ended September 30, 2010, compared to $21.6 million recorded for the three months e
Read more →OSUROraSure Technologies to Participate at the Fifth Annual JMP Securities Healthcare Conference
BETHLEHEM, Pa., Sept. 22, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fifth Annual JMP Securities Healthcare Conference in New York
Read more →OSUROraSure Technologies to Participate at the Canaccord Adams 30th Annual Global Growth Conference
BETHLEHEM, Pa., Aug. 5, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Canaccord Adams 30th Annual Global Growth Conference in Boston a
Read more →OSUROraSure Technologies, Inc. 2010 Second Quarter Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Ronald H. Spair Please see Important Information at the conclusion of the following prepared remarks. Introduction Doug Michels Thanks Judy, and good afternoon everyone. i
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2010 Second Quarter Financial Results - OraSure Also Provides Update on OraQuick HIV Shelf
Chief Financial Officer Investorinfo@orasure.com OraSure Announces 2010 Second Quarter Financial Results - OraSure Also Provides Update on OraQuick HIV Shelf Life Extension and HCV Clinical Program - BETHLEHEM, PA August 4, 2010 (Globe Newswire) OraSure Technologies, Inc.
Read more →OSUROraSure Announces 2010 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 4, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.2 million for the three months ended June 30, 2010, compared to $17.3 million recorded for the three months ended
Read more →OSUROraSure Technologies to Participate at the BMO Capital Markets 10th Annual Focus on Healthcare Conference
BETHLEHEM, Pa., Aug. 3, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the BMO Capital Markets 10th Annual Focus on Healthcare Conference i
Read more →OSUROraSure Technologies Receives FDA Approval for OraQuick(R) HCV Rapid Test, the First Rapid HCV Test Approved for Sale in the U.S.
BETHLEHEM, Pa., June 25, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick Hepatitis C ("HCV") Rapid Antibody Test has been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies in venous wh
Read more →OSUROraSure Technologies and the National Association of People With AIDS Launch Sixth Annual "Mayors Campaign Against HIV(TM)" for National HIV Testing Day
BETHLEHEM, Pa., June 25, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the sixth annual Mayors Campaign Against HIV , a national campaign to encourage testing for HIV and pr
Read more →OSUROraSure Technologies to Participate at ThinkEquity's Mid Year Check-Up on Healthcare
BETHLEHEM, Pa., June 10, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at ThinkEquity's Mid-Year Check-Up on Healthcare Conference in New Yor
Read more →OSUROraSure Technologies to Participate at Jefferies 2010 Global Life Sciences Conference
BETHLEHEM, Pa., June 4, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Jefferies 2010 Global Life Sciences Conference in New York City
Read more →OSUROraSure Technologies to Participate at the Ninth Annual Needham Healthcare Conference
BETHLEHEM, Pa., June 2, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Ninth Annual Needham Healthcare Conference in New York at approx
Read more →OSUROraSure Announces 2010 First Quarter Financial Results
BETHLEHEM, Pa., May 5, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.9 million for the three months ended March 31, 2010, compared to $17.3 million recorded for the three months ended
Read more →OSUROraSure Technologies, Inc. 2010 First Quarter Analyst/Investor Conference Call
OraSure Technologies, Inc. Analyst/Investor Conference Call Prepared Remarks of Douglas A. Michels and Ronald H. Spair Please see Important Information at the conclusion of the following prepared remarks. Introduction Doug Michels Thanks Judy, and good afternoon everyone. w
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2010 First Quarter Financial Results BETHLEHEM, PA
Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2010 First Quarter Financial Results BETHLEHEM, PA May 5, 2010 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics,
Read more →OSUROraSure Announces Fourth Quarter and Full Year 2009 Financial Results
BETHLEHEM, Pa., Feb. 10, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009, respectively. This compares to reve
Read more →OSUROraSure Technologies, Inc. 2009 Fourth Quarter and Full Year Analyst/Investor Conference Call
OraSure Technologies, Inc. 2009 Fourth Quarter and Analyst/Investor Conference Call Douglas A. Michels and Ronald H. Spair Please see Important Information at the conclusion of the following prepared remarks. The following remarks include a discussion of certain non-GAAP fin
Read more →OSURRonald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces Fourth Quarter and Full Year 2009 Financial Results BETHLEHEM, PA
Chief Financial Officer Investorinfo@orasure.com Announces Fourth Quarter and Full Year 2009 Financial Results BETHLEHEM, PA February 10, 2010 (Globe Newswire) OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced revenues of $7
Read more →OSUROraSure CEO Appointed to Presidential Advisory Council on HIV/AIDS
BETHLEHEM, Pa., Feb. 3, 2010 (GLOBE NEWSWIRE) -- Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, was sworn in yesterday by U.S. Health and Human Services Secretary Kathleen Sebelius,
Read more →OSUROraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays
BETHLEHEM, Pa., Jan. 19, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics today announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid drugs of abuse assays with Or
Read more →OSUROraSure Technologies Files Additional Data With FDA in Support of PMA Application for OraQuick Rapid HCV Test
BETHLEHEM, Pa., Jan. 7, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the recent filing of a pre-market approval ("PMA") amendment with the U.S. Food and Drug Administration ("FDA") for the Company's OraQuick(R) Rapid HCV Antibody Test. The ame
Read more →OSUROraSure Technologies to Participate at the Twelfth Annual Needham Growth Conference
BETHLEHEM, Pa., Jan. 5, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Twelfth Annual Needham Growth Conference in New York at approxim
Read more →OSUROraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
BETHLEHEM, Pa., Nov. 19, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE:IMA), Inverness Medical Switzerland GmbH and Church & Dw
Read more →OSUROraSure Technologies Participates in BPAC Meeting on HIV Over-the-Counter Test
BETHLEHEM, Pa., Nov. 18, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it participated in a Blood Products Advisory Committee ("BPAC") meeting held November 17, 2009 in which the BPAC considered, among other topics, the public need and per
Read more →OSUROraSure Announces 2009 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 4, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $21.6 million for the three months ended September 30, 2009, compared to $16.9 million recorded for the three months e
Read more →OSUROraSure Technologies Awarded Premier Contract for Its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test
BETHLEHEM, Pa., Sept. 24, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it has been awarded a 36-month contract for its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test with Premier Purchasing P
Read more →OSUROraSure Technologies to Participate At the UBS Global Life Sciences Conference
BETHLEHEM, Pa., Sept. 17, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City at approx
Read more →OSUROraSure Technologies Appoints Robert A. Gregg, Ph.D. as Vice President, Regulatory Affairs and Quality Assurance
BETHLEHEM, Pa., Sept. 10, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that Robert A. Gregg, Ph.D., has been appointed as the Company's Vice President, Regulatory Affairs and Quality Assurance, eff
Read more →OSUROraSure Technologies Announces 2010 Annual Meeting Date
BETHLEHEM, Pa., Aug. 27, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2010 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 11, 2010. Stockholder proposals must be received no later than December 2, 2009, in orde
Read more →OSUROraSure Announces 2009 Second Quarter Financial Results and Resumption of Full-Scale OraQuick(r) Production
BETHLEHEM, Pa., Aug. 5, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.3 million for the three months ended June 30, 2009, compared to $18.9 million recorded for the three months ended
Read more →OSUROraSure Technologies, Inc. (OSUR) Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, June 25, 2009 (GLOBE NEWSWIRE) -- Doug Michels, Chief Executive Officer of OraSure Technologies, Inc. (OSUR), and Frank Oldham Jr., Executive Director of the National Association of People with AIDS, will preside over the opening bell, with guest Speaker Christine C
Read more →OSUROraSure Technologies, Inc. (OSUR) President and CEO and Mayor Bloomberg to Ring the NASDAQ Stock Market Opening Bell
MEDIA ADVISORY, June 26, 2006 (PRIMEZONE) -- Douglas Michels, President and CEO of OraSure Technologies, Inc. (OSUR), will join New York City Mayor Michael Bloomberg, Frank J. Oldham Jr., Executive Director, the National Association of People with AIDS (NAPWA), and Regan Hofm
Read more →Competitive Position
How OSUR ranks across every disease it competes inCompetitive Position is a premium feature
See how OSUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial